MCID: BRS047
MIFTS: 100

Breast Cancer malady

Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases categories

Aliases & Classifications for Breast Cancer

About this section

Aliases & Descriptions for Breast Cancer:

Name: Breast Cancer 49 10 11 68 23 47 12 35 2 67
Breast Carcinoma 10 23 47 12 65 67
Male Breast Cancer 10 68 45 12 35
Malignant Neoplasm of Breast 10 68 23 65
Cancer of Breast 68 23 24
Mammary Cancer 10 68 23
Malignant Neoplasm of Male Breast 10 65
Invasive Ductal Breast Carcinoma 47 65
Breast Cancer, Invasive Ductal 49 32
Breast Cancer, Early-Onset 49 24
Malignant Tumor of Breast 68 23
Breast Cancer, Lobular 49 32
Breast Cancer, Somatic 49 22
Breast Male Carcinoma 47 24
Breast Cancer, Male 49 45
Mammary Carcinoma 10 67
Mammary Tumor 10 47
Primary Malignant Neoplasm of Breast 65
Breast Cancer, Protection Against 49
 
Malignant Tumor of the Breast 10
Breast Cancer Susceptibility 49
Breast Cancer Familial Male 67
Animal Mammary Neoplasms 65
Breast Lobular Carcinoma 10
Carcinoma of Male Breast 65
Neoplasm of Male Breast 10
Carcinoma of Breast Nos 10
Breast Cancer, Familial 23
Breast Neoplasms, Male 65
Breast Cancer Familial 67
Primary Breast Cancer 10
Male Breast Carcinoma 45
Breast Cancer in Men 45
Carcinoma of Breast 10
Mammary Neoplasms 65
Breast Neoplasms 36
Breast Tumor 10
Bc 67


Classifications:



Summaries for Breast Cancer

About this section
MedlinePlus:35 Breast cancer affects one in eight women during their lives. breast cancer kills more women in the united states than any cancer except lung cancer. no one knows why some women get breast cancer, but there are a number of risk factors. risks that you cannot change include age - the chance of getting breast cancer rises as a woman gets older genes - there are two genes, brca1 and brca2, that greatly increase the risk. women who have family members with breast or ovarian cancer may wish to be tested. personal factors - beginning periods before age 12 or going through menopause after age 55 other risks include being overweight, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35 or having dense breasts. symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. breast self-exam and mammography can help find breast cancer early when it is most treatable. treatment may consist of radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy. men can have breast cancer, too, but the number of cases is small. nih: national cancer institute

MalaCards based summary: Breast Cancer, also known as breast carcinoma, is related to prostate cancer and colorectal cancer, and has symptoms including autosomal dominant inheritance, heterogeneous and breast carcinoma. An important gene associated with Breast Cancer is BRCA2 (Breast Cancer 2, Early Onset), and among its related pathways are Integrated Breast Cancer Pathway and DNA Double-Strand Break Repair. The drugs aminoglutethimide and chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related mouse phenotypes are mortality/aging and cellular.

Disease Ontology:10 A thoracic cancer that originates in the mammary gland.

Genetics Home Reference:23 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.

OMIM:49 Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly... (114480) more...

CDC:2 Other than skin cancer, breast cancer is the most common cancer among American women. Getting mammograms regularly can lower the risk of dying from breast cancer. The United States Preventive Services Task Force recommends that if you are 50 to 74 years old, be sure to have a screening mammogram every two years. If you are 40 to 49 years old, talk to your doctor about when to start and how often to get a screening mammogram.

Novus Biologicals:48 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

UniProtKB/Swiss-Prot:67 Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

Wikipedia:68 Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Related Diseases for Breast Cancer

About this section

Diseases in the Breast Cancer family:

Sporadic Breast Cancer Inflammatory Breast Carcinoma
Breast Benign Neoplasm Breast Carcinoma in Situ
Familial Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Chek2-Related Susceptibility to Breast Cancer
Rad51-Related Susceptibility to Breast Cancer

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 2114)
idRelated DiseaseScoreTop Affiliating Genes
1prostate cancer32.5AKT1, ATM, BRCA1, BRCA2, CASP8, CDH1
2colorectal cancer32.3AKT1, BRCA1, BRCA2, CASP8, CDH1, CHEK2
3female reproductive system disease32.3AKT1, BRCA1, BRCA2, CDH1, KRAS, PIK3CA
4male reproductive system disease32.0AKT1, BRCA1, BRCA2, CDH1, CHEK2
5aplastic anemia32.0BRCA2, BRIP1, PALB2, TP53
6renal cell carcinoma31.9AKT1, ATM, CDH1, KRAS, PIK3CA, TP53
7ataxia-telangiectasia31.9AGTR1, ATM, BRCA1, BRCA2, CHEK2, TP53
8peripheral neuropathy31.9AKT1, BARD1, TP53
9breast cyst31.8BRCA1, BRCA2, TP53
10nutritional deficiency disease31.7BRCA1, BRCA2
11stomach disease31.6CDH1, KRAS, PIK3CA, TP53
12amyloid tumor31.6BRCA1, BRCA2, PIK3CA, TP53
13breast cancer, childhood31.6BRCA1, BRCA2, CHEK2, PALB2
14gastrointestinal system disease31.5AKT1, CDH1, CHEK2, KRAS, PIK3CA, TP53
15esophageal cancer31.5AKT1, CDH1, CHEK2, KRAS, PIK3CA, TP53
16brca2 hereditary breast and ovarian cancer syndrome31.5BRCA1, BRCA2, CHEK2, PALB2
17thyroid gland disease31.5CDH1, KRAS, PIK3CA, TP53
18thrombophilia31.4AKT1, ATM, BARD1, BRCA1, BRCA2, BRIP1
19nervous system disease31.4AKT1, BARD1, TP53
20nijmegen breakage syndrome31.3ATM, BRCA1, CHEK2, TP53
21lung cancer susceptibility 331.3CDH1, KRAS, TP53
22kidney disease31.3AKT1, ATM, CASP8, PIK3CA, TP53
23breast squamous cell carcinoma31.3BRCA1, BRCA2, CDH1
24bronchiolitis obliterans31.2BRCA1, BRCA2
25breast adenoma31.2AKT1, PIK3CA, TP53
26cellulitis31.2AKT1, ATM, BRCA1, CDH1, KRAS, PIK3CA
27precursor lymphoblastic lymphoma/leukemia31.2BRCA1, BRCA2, CDH1, TP53
28bile duct adenocarcinoma31.1ATM, BRCA1, BRCA2, CHEK2, RAD51
29pancreatic islet cell tumors31.1BRCA1, BRCA2, KRAS, PALB2, TP53
30ovarian cancer, somatic31.1AKT1, BRCA1, BRCA2, CDH1, KRAS, PALB2
31macrocytic anemia31.0BRCA1, BRCA2, KRAS, TP53
32pathological gambling31.0BRCA1, BRCA2, TP53
33adenofibroma31.0AKT1, CDH1, KRAS, TP53
34malignant peripheral nerve sheath tumor30.9BRCA1, BRCA2, CDH1, KRAS, PIK3CA, TP53
35gastric cancer, somatic30.9CDH1, KRAS, PIK3CA
36gallbladder disease30.9CDH1, KRAS, TP53
37extrahepatic bile duct small cell adenocarcinoma30.8BRCA1, BRCA2
38pancreatic ductal adenocarcinoma30.8AKT1, CDH1, KRAS, TP53
39pancreatic somatostatinoma30.8AKT1, CDH1, KRAS, TP53
40auricular cancer30.7AKT1, CDH1, TP53
41malignant mixed mullerian tumor30.7PIK3CA, TP53
42breast disease11.7
43li-fraumeni syndrome11.7
44skin benign neoplasm11.6
45female breast carcinoma11.5
46skin disease11.3
47familial breast cancer11.3
48estrogen-receptor positive breast cancer11.3
49skin tag11.3
50estrogen-receptor negative breast cancer11.3

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to breast cancer

Symptoms for Breast Cancer

About this section

Symptoms by clinical synopsis from OMIM:

114480

Clinical features from OMIM:

114480

HPO human phenotypes related to Breast Cancer:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 heterogeneous HP:0001425
3 breast carcinoma HP:0003002

Drugs & Therapeutics for Breast Cancer

About this section

FDA approved drugs:

(show all 20)
id Drug Name Active Ingredient(s)15 Company Approval Date
1
Afinitor 15 41 EVEROLIMUS Novartis March 2009
FDA Label: Afinitor
Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer
Indications and Usage:15 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:13 Serine/threonine-protein kinase mTOR
Mechanism of Action:15 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
2
Aredia15 41 PAMIDRONATE DISODIUM Chiron August 1996
FDA Label: Aredia
Disease/s that Drug Treats:osteolytic bone metastases of breast cancer
Indications and Usage:15 Hypercalcemia of MalignancyAredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severehypercalcemia associated with malignancy, with or without bone metastases. Patients who have eitherepidermoid or non-epidermoid tumors respond to treatment with Aredia. Vigorous saline hydration, anintegral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made torestore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia maybe treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patientsshould be hydrated adequately throughout the treatment, but overhydration, especially in those patientswho have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction ofhypovolemia. The safety and efficacy of Aredia in the treatment of hypercalcemia associated withhyperparathyroidism or with other non-tumor-related conditions has not been established.Paget’s DiseaseAredia is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. Theeffectiveness of Aredia was demonstrated primarily in patients with serum alkaline phosphatase ≥3 timesthe upper limit of normal. Aredia therapy in patients with Paget’s disease has been effective in reducingserum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by≥30% in at least 80% of patients. Aredia therapy has also been effective in reducing these biochemicalmarkers in patients with Paget’s disease who failed to respond, or no longer responded to othertreatments.Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of MultipleMyelomaAredia is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolyticbone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Aredia treatment effectappeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the studyof those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated(see CLINICAL PHARMACOLOGY, Osteolytic Bone Metastases of Breast Cancer and OsteolyticLesions of Multiple Myeloma, Clinical Trials section).
DrugBank Targets:13 1. Farnesyl pyrophosphate synthase;2. Hydroxylapatite
Mechanism of Action:15 
Target: bone resorption; FPP synthase
Action: inhibitor
FDA: The principal pharmacologic action of Aredia is inhibition of bone resorption. Although the mechanism ofantiresorptive action is not completely understood, several factors are thought to contribute to this action.Aredia adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolutionof this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activitycontributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment ofhypercalcemia, Aredia inhibits bone resorption apparently without inhibiting bone formation andmineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that Arediainhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by varioustumors in animal studies.
3
Arimidex15 41 ANASTROZOLE AstraZeneca January 1996
FDA Label: Arimidex
Disease/s that Drug Treats:post menopausal breast cancer
Indications and Usage:15 ARIMIDEX is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women withhormone receptor-positive early breast cancer (1.1) First-line treatment of postmenopausal women withhormone receptor-positive or hormone receptor unknownlocally advanced or metastatic breast cancer (1.2) Treatment of advanced breast cancer in postmenopausalwomen with disease progression following tamoxifentherapy. Patients with ER-negative disease and patientswho did not respond to previous tamoxifen therapy rarelyresponded to ARIMIDEX (1.3)
DrugBank Targets:13 Cytochrome P450 19A1
Mechanism of Action:15 
Target: oral aromatase
Action: inhibitor
FDA: The growth of many cancers of the breast is stimulated or maintained by estrogens.In postmenopausal women, estrogens are mainly derived from the action of the aromataseenzyme, which converts adrenal androgens (primarily androstenedione and testosterone) toestrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and inthe cancer tissue itself can therefore be achieved by specifically inhibiting the aromataseenzyme.Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serumestradiol concentrations and has no detectable effect on formation of adrenal corticosteroidsor aldosterone.
4
Aromasin Tablets15 41 EXEMESTANE Pharmacia & Upjohn October 21. 1999
FDA Label: Aromasin Tablets
Disease/s that Drug Treats:advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Indications and Usage:15 AROMASIN is an aromatase inhibitor indicated for: Incidences of cardiac ischemic events (myocardial infarction, angina, adjuvant treatment of postmenopausal women with estrogen-receptor and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%.positive early breast cancer who have received two to three years of Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6,tamoxifen and are switched to AROMASIN for completion of a total of 6.1).five consecutive years of adjuvant hormonal therapy (14.1). Advanced breast cancer: Most common adverse events were mild to treatment of advanced breast cancer in postmenopausal women whose moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%),disease has progressed following tamoxifen therapy (14.2).
DrugBank Targets:13 Cytochrome P450 19A1
Mechanism of Action:15 
Target: steroidal aromatase
Action: inactivator
FDA: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that convertsandrogens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarilyestradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausalwomen is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens(estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromataseinhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breastcancer.Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrateandrostenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that bindsirreversibly to the active site of the enzyme, causing its inactivation, an effect also known as “suicide inhibition.”Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has nodetectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on otherenzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibitingthe aromatase enzyme.
5
Ellence15 41 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
FDA Label: Ellence
Disease/s that Drug Treats:Component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer
Indications and Usage:15 ELLENCE Injection is an anthracycline topoisomerase II inhibitor indicatedas a component of adjuvant therapy in patients with evidence of axillary nodetumor involvement following resection of primary breast cancer (1).
DrugBank Targets:13 1. Chromodomain-helicase-DNA-binding protein 1;2. DNA topoisomerase 2-alpha;3. DNA
Mechanism of Action:15 
Target: nucleic acid (DNA and RNA) and protein synthesis
Action: inhibitor
FDA: Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical andbiological functions within eukaryotic cells, the precise mechanisms of epirubicin’s cytotoxic and/or antiproliferative properties have not beencompletely elucidated.Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleicacid (DNA and RNA) and protein synthesis.Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity,preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved inoxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to resultfrom these or other possible mechanisms.Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also activein vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.
6
Evista15 41 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
FDA Label: Evista
Disease/s that Drug Treats:osteoporosis and reduction of breast cancer risk in postmenopausal women
Indications and Usage:15 EVISTA is an estrogen agonist/antagonist indicated for Treatment and prevention of osteoporosis in postmenopausal women.(1.1)
DrugBank Targets:13 1. Estrogen receptor;2. Estrogen receptor beta
Mechanism of Action:15 
Target: estrogenic pathways
Action: can be an activator or antooagonist
FDA: Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption andaccelerated bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation isinadequate to offset resorptive losses. In addition to loss of estrogen, this imbalance between resorption andformation may be due to age-related impairment of osteoblasts or their precursors. In some women, these changeswill eventually lead to decreased bone mass, osteoporosis, and increased risk for fractures, particularly of the spine,hip, and wrist. Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This bindingresults in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is an estrogenagonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM).Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to thepremenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of boneturnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineraldensity (BMD), and decreases in incidence of fractures.
7
Faslodex15 41 FULVESTRANT AstraZeneca April 2002
FDA Label: Faslodex
Disease/s that Drug Treats:Hormone receptor positive metastatic breast cancer
Indications and Usage:15 FASLODEX is an estrogen receptor antagonist indicated for the: Treatment of hormone receptor positive metastatic breast cancer inpostmenopausal women with disease progression followingantiestrogen therapy.
DrugBank Targets:13 1. Estrogen receptor
Mechanism of Action:15 
Target: estrogen receptors on tumor cells
Action: antagonist
FDA: Many breast cancers have estrogen receptors (ER) and thegrowth of these tumors can be stimulated by estrogen.Fulvestrant is an estrogen receptor antagonist that binds to theestrogen receptor in a competitive manner with affinitycomparable to that of estradiol and downregulates the ERprotein in human breast cancer cells.In vitro studies demonstrated that fulvestrant is a reversibleinhibitor of the growth of tamoxifen-resistant, as well asestrogen-sensitive human breast cancer (MCF-7) cell lines. Inin vivo tumor studies, fulvestrant delayed the establishment oftumors from xenografts of human breast cancer MCF-7 cellsin nude mice. Fulvestrant inhibited the growth of establishedMCF-7 xenografts and of tamoxifen-resistant breast tumorxenografts.Fulvestrant showed no agonist-type effects in in vivouterotropic assays in immature or ovariectomized mice andrats. In in vivo studies in immature rats and ovariectomizedmonkeys, fulvestrant blocked the uterotrophic action ofestradiol. In postmenopausal women, the absence of changesin plasma concentrations of FSH and LH in response tofulvestrant treatment (250 mg monthly) suggests no peripheralsteroidal effects.
8
Femara15 41 LETROZOLE Novartis January 2001
FDA Label: Femara
Disease/s that Drug Treats:Hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer
Indications and Usage:15 Femara is an aromatase inhibitor indicated for: Adjuva nt treatment of postmenopausal women with hormone receptorpositive early brea st cancer (1.1) Extended adjuvant treatment of postmenopausal women with early brea stcancer who have received prior standard adju vant ta moxifen thera py (1.2) First a nd second-line treatment of postmenopausal women with hormonereceptor positive or unknown advanced breast cancer (1.3)
DrugBank Targets:13 1. Cytochrome P450 19A1
Mechanism of Action:15 
Target: aromatase enzyme system
Action: inhibitor
FDA: The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breastcancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive orreceptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy,adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents).These interventions lead to decreased tumor mass or delayed progression of tumor growth in somewomen.In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, whichconverts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. Thesuppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore beachieved by specifically inhibiting the aromatase enzyme.Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits theconversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole isas effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression ofestrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to anincrease in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effecton adrenal mineralocorticoid or glucocorticoid synthesis.Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of womenwith letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown tosignificantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroidhormones.
9
Halaven15 41 ERIBULIN MESYLATE Eisai November 2010
FDA Label: Halaven
Disease/s that Drug Treats:metastatic breast cancer
Indications and Usage:15 HALAVEN is a microtubule inhibitor indicated for the treatment ofpatients with metastatic breast cancer who have previously receivedat least two chemotherapeutic regimens for the treatment ofmetastatic disease. Prior therapy should have included ananthracycline and a taxane in either the adjuvant or metastaticsetting (1)
DrugBank Targets:13 -
Mechanism of Action:15 
Target: microtubule dynamics
Action: inhibitor
FDA: Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesterstubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitoticmechanism leading to G 2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic celldeath after prolonged mitotic blockage
10
Herceptin15 41 TRASTUZUMAB Genentech October 1998
FDA Label: Herceptin
Disease/s that Drug Treats:Breast cancer/gastric cancer
Indications and Usage:15 Herceptin is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer (1.1, 1.2). the treatment of HER2-overexpressing metastatic gastric orgastroesophageal junction adenocarcinoma (1.3)
DrugBank Targets:13 1. Receptor tyrosine-protein kinase erbB-2;2. Epidermal growth factor receptor;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. Low affinity immunoglobulin gamma Fc region receptor III-B;13. Low affinity immunoglobulin gamma Fc region receptor III-A
Mechanism of Action:15 
Target: human epidermal growth factor receptor 2 protein (HER2)
Action: binds with strong affinity for immune response
FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
11
Ibrance15 41 PALBOCICLIB Pfizer February 2015
FDA Label: Ibrance
Disease/s that Drug Treats:ER-positive, HER2-negative breast cancer
Indications and Usage:15 IBRANCE is a kinase inhibitor indicated in combination with letrozole for thetreatment of postmenopausal women with estrogen receptor (ER)-positive,human epidermal growth factor receptor 2 (HER2)-negative advanced breastcancer as initial endocrine-based therapy for their metastatic disease. Thisindication is approved under accelerated approval based on progression-freesurvival (PFS). Continued approval for this indication may be contingentupon verification and description of clinical benefit in a confirmatory trial. (1)
DrugBank Targets:13 1. Cyclin-dependent kinase 4;2. Cyclin-dependent kinase 6
Mechanism of Action:15 
Target: cyclin-dependent kinase (CDK) 4 and 6
Action: inhibitor
FDA: Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4/6 aredownstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reducedcellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progressionof the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with thecombination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb)phosphorylation resulting in reduced E2F expression and signaling and increased growth arrestcompared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lineswith the combination of palbociclib and antiestrogens leads to increased cell senescence, which wassustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positivebreast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increasedthe inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drugalone.
12
Inform HER-2/neu breast cancer test15 Oncor January 1998
FDA Label: -
Disease/s that Drug Treats:breast cancer prediction
Indications and Usage:15 -
DrugBank Targets: -
Mechanism of Action:15 
Target: -
Action: -
FDA: -
13
Ixempra15 41 IXABEPILONE Bristol-Myers Squibb October 2007
FDA Label: Ixempra
Disease/s that Drug Treats:Breast cancer
Indications and Usage:15 IXEMPRA, a microtubule inhibitor, in combination with capecitabine isindicated for the treatment of metastatic or locally advanced breastcancer in patients after failure of an anthracycline and a taxane (1). IXEMPRA as monotherapy is indicated for the treatment of metastaticor locally advanced breast cancer in patients after failure of ananthracycline, a taxane, and capecitabine (1).
DrugBank Targets:13 1. Tubulin beta-3 chain
Mechanism of Action:15 
Target: β-tubulin subunits on microtubules
Action: suppressor of dynamics
FDA: Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directlyto β-tubulin subunits on microtubules, leading to suppression of microtubule dynamics.Ixabepilone suppresses the dynamic instability of αβ-II and αβ-III microtubules.Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepiloneblocks cells in the mitotic phase of the cell division cycle, leading to cell death.
14
Kadcyla15 41 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
FDA Label: Kadcyla
Disease/s that Drug Treats:HER2-positive metastatic breast cancer
Indications and Usage:15 KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugateindicated, as a single agent, for the treatment of patients with HER2-positive,metastatic breast cancer who previously received trastuzumab and a taxane,separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or Developed disease recurrence during or within six months ofcompleting adjuvant therapy. (1)
DrugBank Targets:13 1. Receptor tyrosine-protein kinase erbB-2
Mechanism of Action:15 
Target: microtubule
Action: inhibitor
FDA: Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate. The antibody is thehumanized anti-HER2 IgG1, trastuzumab. The small molecule cytotoxin, DM1, is a microtubuleinhibitor. Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansineundergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting inintracellular release of DM1-containing cytotoxic catabolites. Binding of DM1 to tubulindisrupts microtubule networks in the cell, which results in cell cycle arrest and apoptotic celldeath. In addition, in vitro studies have shown that similar to trastuzumab, ado-trastuzumabemtansine inhibits HER2 receptor signaling, mediates antibody-dependent cell-mediatedcytotoxicity and inhibits shedding of the HER2 extracellular domain in human breast cancer cellsthat overexpress HER2.
15
Miraluma Test15 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
FDA Label: Miraluma Test
Disease/s that Drug Treats:breast imaging
Indications and Usage:15 Breast Imaging: MIRALUMA, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. MIRALUMA is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.
DrugBank Targets: -
Mechanism of Action:15 
Target: malignant cells
Action: accumulates
FDA: The mechanism of Tc99m Sestanibi localization in various types of breast tissue (e.g. beinign, inflammatory, malignant, fiborous) has not been established.
16
Nolvadex15 41 TAMOXIFEN CITRATE AstraZeneca October 1998
FDA Label: Nolvadex
Disease/s that Drug Treats:Breast Cancer
Indications and Usage:15 Metastatic Breast Cancer:NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. Inpremenopausal women with metastatic breast cancer, NOLVADEX is an alternative tooophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumorsare estrogen receptor positive are more likely to benefit from NOLVADEX therapy.Adjuvant Treatment of Breast Cancer:NOLVADEX is indicated for the treatment of node-positive breast cancer in women followingtotal mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In someNOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four ormore positive axillary nodes.NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in womenfollowing total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.The estrogen and progesterone receptor values may help to predict whether adjuvantNOLVADEX therapy is likely to be beneficial.NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvantNOLVADEX therapy for breast cancer.Ductal Carcinoma in Situ (DCIS):In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated toreduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of thelabel). The decision regarding therapy with NOLVADEX for the reduction in breast cancerincidence should be based upon an individual assessment of the benefits and risks ofNOLVADEX therapy.Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patientswith breast cancer. Reduction in Breast Cancer Incidence in High Risk Women:NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk forbreast cancer. This effect was shown in a study of 5 years planned duration with a medianfollow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. Thelonger-term effects are not known. In this study, there was no impact of tamoxifen on overall orbreast cancer-related mortality (see BOXED WARNING at the beginning of the label).NOLVADEX is indicated only for high-risk women. “High risk” is defined as women at least35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the GailModel.Examples of combinations of factors predicting a 5-year risk ≥ 1.67% are:Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and ahistory of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of atleast one breast biopsy; or LCISAge 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at firstlive birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 oryounger; or One first degree relative with a history of breast cancer, and a personal history of a breastbiopsy showing atypical hyperplasia.Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 oryounger; or One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, age at menarche 11 or less and age at first live birth 20 or more.Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 orolder and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at firstlive birth 30 or more.Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first livebirth 20 or older.Age 60 or older and: 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.For women whose risk factors are not described in the above examples, the Gail Model isnecessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a GailModel Risk Assessment Tool by dialing 1-800-544-2007.There are insufficient data available regarding the effect of NOLVADEX on breast cancerincidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specificrecommendations on the effectiveness of NOLVADEX in these patients.After an assessment of the risk of developing breast cancer, the decision regarding therapy withNOLVADEX for the reduction in breast cancer incidence should be based upon an individualassessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial,NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up periodof the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICALPHARMACOLOGY).
DrugBank Targets:13 1. Estrogen receptor;2. Estrogen receptor beta;3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;4. Protein kinase C
Mechanism of Action:15 
Target: estrogen receptors
Action: competitor with estraidiol
FDA: NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties inanimal test systems. The antiestrogenic effects may be related to its ability to compete withestrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of ratmammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression ofalready established DMBA-induced tumors. In this rat model, tamoxifen appears to exert itsantitumor effects by binding the estrogen receptors.In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol forestrogen receptor protein.
17
Perjeta15 41 PERTUZUMAB Genentech June 2012
FDA Label: Perjeta
Disease/s that Drug Treats:HER2+ metastatic breast cancer
Indications and Usage:15 PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment ofpatients with HER2-positive metastatic breast cancer (MBC) who havenot received prior anti-HER2 therapy or chemotherapy for metastaticdisease. (1.1) Use in combination with trastuzumab and docetaxel as neoadjuvanttreatment of patients with HER2-positive, locally advanced,inflammatory, or early stage breast cancer (either greater than 2 cm indiameter or node positive) as part of a complete treatment regimen forearly breast cancer. This indication is based on demonstration of animprovement in pathological complete response rate. No data areavailable demonstrating improvement in event-free survival or overallsurvival. (1.2, 2.1, 14.2)Limitations of Use: The safety of PERJETA as part of a doxorubicin-containing regimenhas not been established. The safety of PERJETA administered for greater than 6 cycles forearly breast cancer has not been established.
DrugBank Targets:13 1. Receptor tyrosine-protein kinase erbB-2
Mechanism of Action:15 
Target: mitogen-activated protein (MAP) kinase, phosphoinositide 3-kinase445 (PI3K)
Action: inhibitor of ligand-initiated intracellular signaling
FDA: Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways, mitogen-activated protein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC). While pertuzumab alone inhibited the proliferation of human tumor cells, the combination of pertuzumab and trastuzumab augmented anti-tumor activity in HER2-overexpressing xenograft models.
18
Taxotere15 41 DOCETAXEL Rhone Poulenc Rorer May 1996
FDA Label: Taxotere
Disease/s that Drug Treats:breast cancer
Indications and Usage:15 TAXOTERE is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BCafter chemotherapy failure; and with doxorubicin andcyclophosphamide as adjuvant treatment of operable node-positive BC(1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locallyadvanced or metastatic NSCLC after platinum therapy failure; andwith cisplatin for unresectable, locally advanced or metastaticuntreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone inandrogen independent (hormone refractory) metastatic prostate cancer(1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil foruntreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):with cisplatin and fluorouracil for induction treatment of locallyadvanced SCCHN (1.5)
DrugBank Targets:13 1. Tubulin beta-1 chain;2. Apoptosis regulator Bcl-2;3. Microtubule-associated protein 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein tau;6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:15 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that isessential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes theassembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. Thisleads to the production of microtubule bundles without normal function and to the stabilization ofmicrotubules, which results in the inhibition of mitosis in cells. Docetaxel’s binding to microtubulesdoes not alter the number of protofilaments in the bound microtubules, a feature which differs from mostspindle poisons currently in clinical use.
19
Tykerb15 41 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
FDA Label: Tykerb
Disease/s that Drug Treats:breast cancer
Indications and Usage:15 TYKERB, a kinase inhibitor, is indicated in combination with: (1) capecitabine, for the treatment of patients with advanced or metastatic breastcancer whose tumors overexpress HER2 and who have received prior therapyincluding an anthracycline, a taxane, and trastuzumab.Limitation of Use: Patients should have disease progression on trastuzumabprior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptorpositivemetastatic breast cancer that overexpresses the HER2 receptor forwhom hormonal therapy is indicated.TYKERB in combination with an aromatase inhibitor has not been comparedto a trastuzumab-containing chemotherapy regimen for the treatment ofmetastatic breast cancer.
DrugBank Targets:13 1. Epidermal growth factor receptor;2. Receptor tyrosine-protein kinase erbB-2
Mechanism of Action:15 
Target: Epidermal Growth Factor Receptor (EGFR [ErbB1]), Human Epidermal Receptor Type 2 (HER-2 [ErbB2]) receptor
Action: inhibitor intracellular tyrosine kinase domains
FDA: Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinasedomains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human EpidermalReceptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM,respectively) with a dissociation half-life of 300 minutes. Lapatinib inhibits ErbB-driven tumorcell growth in vitro and in various animal models.An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (theactive metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. Thegrowth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines.Lapatinib retained significant activity against breast cancer cell lines selected for long-termgrowth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-crossresistancebetween these two agents.Hormone receptor-positive breast cancer cells (with ER [Estrogen Receptor] and/or PgR[Progesterone Receptor]) that coexpress the HER2 tend to be resistant to established endocrinetherapies. Similarly, hormone receptor-positive breast cancer cells that initially lack EGFR orHER2 upregulate these receptor proteins as the tumor becomes resistant to endocrine therapy.
20
Xeloda15 41 CAPECITABINE Roche April 1998/ May 2001
FDA Label: Xeloda
Disease/s that Drug Treats:breast cancer/ metastatic colorectal cancer
Indications and Usage:15 XELODA (capecitabine) is a nucleoside metabolic inhibitor withantineoplastic activity indicated for: Adjuv ant Colon Cancer (1.1)- Patients with Dukes’ C colon cancer Metastatic Colorectal Cancer (1.1)- First-line as monotherapy when treatment with fluoropyrimidinetherapy alone is preferred Metastatic Breast Cancer (1.2)- In combination with docetaxel after failure of prior anthracyclinecontainingtherapy- As monotherapy in patients resistant to both paclitaxel and ananthracycline-containing regimen
DrugBank Targets:13 1. Thymidylate synthase;2. DNA;3. RNA
Mechanism of Action:15 
Target: capecitabine
Action: converted to 5-fluorouracil (5-FU) --> cause cell injury
FDA: Enzymes convert capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cellsmetabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridinetriphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First,FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase(TS) to form a covalently bound ternary complex. This binding inhibits the formation ofthymidylate from 2’-deoxyuridylate. Thymidylate is the necessary precursor of thymidinetriphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compoundcan inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporateFUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic errorcan interfere with RNA processing and protein synthesis.
cause cell injury
Medilexicon: Xeloda is the first oral drug that works through enzymatic activation of the cancer fighting substance fluorouracil (5-FU). Once in the body, Xeloda is converted into 5-FU by the naturally produced enzyme thymidine phosphorylase (TP).
FDA: Enzymes convert capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cellsmetabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridinetriphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First,FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase(TS) to form a covalently bound ternary complex. This binding inhibits the formation ofthymidylate from 2’-deoxyuridylate. Thymidylate is the necessary precursor of thymidinetriphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compoundcan inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporateFUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic errorcan interfere with RNA processing and protein synthesis.
Drug info:
-->

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 687)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Trastuzumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0688180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
2
ado-trastuzumab emtansineapprovedPhase 4, Phase 3, Phase 2, Phase 1571018448-65-1
Synonyms:
Kadcyla
 
Trastuzumab-DM1
trastuzumab emtansine
trastuzumab-MCC-DM1
3
EpirubicinapprovedPhase 4, Phase 3, Phase 2, Phase 134356420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
4
Vinorelbineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 133971486-22-160780, 44424639
Synonyms:
5'-Noranhydrovinblastine
71486-22-1
AC1L1KVK
AC1L1TWQ
AC1L75Q4
ANX-530
Ambap71486-22-1
BIDD:PXR0186
C45H54N4O8
CHEBI:480999
CHEMBL607994
CID355119
CID5311497
CID5672
CID60780
CID6426842
D08680
DB00361
Eunades
Exelbine
HMS2090E13
HSDB 7665
I06-0084
I06-0085
KW 2307
KW 2307 base
KW-2307
 
LS-97533
MolPort-006-822-661
MolPort-006-823-869
NCGC00165966-02
NVB
Navelbine
Navelbine (TN)
Navelbine Base
Navelbine base
Nor-5'-anhydrovinblastine
SDP-012
UNII-Q6C979R91Y
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
Vinorelbine
Vinorelbine (INN)
Vinorelbine Bitartrate
Vinorelbine Ditartarate
Vinorelbine Ditartrate
Vinorelbine Tartrate
Vinorelbine [INN:BAN]
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
vinorelbine
5
AmpicillinapprovedPhase 45069-53-46249
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
1h8s
33604-21-6
37234-64-3
47355-94-2
50584-05-9
6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid
6-(D-(2-amino-2-Phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
6-(a-Aminophenylacetamido)penicillanic acid
6-D(-)-alpha-Aminophenylacetamido-penicillanic acid
6-[(Aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI
69-52-3 (mono-hydrochloride salt)
69-53-4
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
7177-48-2 (TRIHYDRATE)
800-79-3
8056-87-9
96707-69-6
98520-55-9
A9393_SIGMA
AB-PC
AB-PC Sol
ABPC
AC-14075
AC1L1M46
AMP
AMPI
AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2)
AP
AY 6108
AY 6108
AY-6108
Acillin
Adobacillin
Alpen
Amblosin
Amcill
Amfipen
Amfipen V
Amfipen v
Aminobenzylpenicillin
Amipenix S
Ampen
Ampi-Co
Ampi-Tab
Ampi-bol
Ampi-co
Ampi-tab
Ampichel
Ampicil
Ampicilina
Ampicilina [INN-Spanish]
Ampicillin
Ampicillin (USP/INN)
Ampicillin A
Ampicillin Acid
Ampicillin Anhydrate
Ampicillin Anhydrous
Ampicillin Base
Ampicillin Sodium
Ampicillin Trihydrate
Ampicillin [USAN:BAN:INN:JAN]
Ampicillin [USAN:INN:BAN:JAN]
Ampicillin [Usan:Ban:Inn:Jan]
Ampicillin acid
Ampicillin anhydrate
Ampicillin sodium
Ampicillina
Ampicillina [DCIT]
Ampicillina [Dcit]
Ampicilline
Ampicilline [INN-French]
Ampicillinum
Ampicillinum [INN-Latin]
Ampicin
Ampifarm
Ampikel
Ampimed
Ampipenin
Ampipenin, nt3
Ampiscel
Ampisyn
Ampivax
Ampivet
Amplacilina
Amplin
Amplipenyl
Amplisom
Amplital
Ampy-Penyl
Anhydrous Ampicillin
Anhydrous ampicillin
Anhydrous ampicillin (JP15)
Austrapen
BA 7305
BIDD:GT0184
BPBio1_000142
BRL 1341
BRL-1341
BSPBio_000128
BSPBio_001862
Bayer 5427
Binotal
Bonapicillin
Britacil
C06574
CHEBI:28971
CHEBI:53713
CHEMBL174
CID6249
Campicillin
Cimex
Copharcilin
D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid
D-(-)-6-(alpha-aminophenylacetamido)penicillanic acid
D-(-)-Ampicillin
D-(-)-alpha-Aminobenzylpenicillin
D-(-)-alpha-Aminopenicillin
D-(-)-ampicillin
D-(−)-6-(α-aminophenylacetamido)penicillanic acid
D-(−)-ampicillin
D-Ampicillin
D-Cillin
D-a-Aminobenzylpenicillin
D00204
DB00415
Delcillin
Deripen
 
DivK1c_000466
Divercillin
Doktacillin
Duphacillin
EINECS 200-709-7
Geocillin
Grampenil
Guicitrina
Guicitrine
HI 63
HMS2090I11
HSDB 3009
IDI1_000466
KBio1_000466
KBio2_000430
KBio2_002998
KBio2_005566
KBio3_001362
KBioGR_000598
KBioSS_000430
KS-R1
LS-1586
LS-169948
Lifeampil
MLS000028405
MLS001074168
Magnapen
Marcillin
MolPort-001-794-635
Morepen
NCGC00023282-05
NCGC00023282-06
NINDS_000466
NSC 528986
NSC-528986
NSC528986
Norobrittin
Novo-ampicillin
Nuvapen
OMNIPEN (AMPICILLIN)
Olin Kid
Olin kid
Omnipen
Omnipen (TN)
Omnipen-N
Orbicilina
P 50
P-50
Pen A
Pen A Oral
Pen Ampil
Pen a
Pen ampil
Penbristol
Penbritin
Penbritin paediatric
Penbritin syrup
Penbritin-S
Penbrock
Penicillin, Aminobenzyl
Penicline
Penimic
Pensyn
Pentrex
Pentrexl
Pentrexyl
Pentritin
Pfizerpen A
Pfizerpen a
Pfizerpen-A
Polycillin
Polycillin-N
Polyflex (Veterinary)
Ponecil
Prestwick0_000114
Prestwick1_000114
Prestwick2_000114
Prestwick3_000114
Princillin
Principen
Principen '125'
Principen '250'
Principen '500'
QIDamp
Qidamp
Racenacillin
Ro-Ampen
Ro-ampen
Rosampline
Roscillin
SBB063111
SK-Ampicillin
SK-ampicillin
SMP1_000211
SMR000058352
SPBio_000818
SPBio_002067
SQ 17382
Semicillin
Semicillin R
Servicillin
Spectrum2_000769
Spectrum3_000301
Spectrum4_000149
Spectrum5_000814
Spectrum_000050
Sumipanto
Supen
Synpenin
Texcillin
Tokiocillin
Tolomol
Totacillin
Totacillin (sodium)
Totacillin-N
Totalciclina
Totapen
Trifacilina
UNII-7C782967RD
Ukapen
Ultrabion
Ultrabron
Vampen
Viccillin
Viccillin S
Vidocillin
Vidopen
WY-5103
Wypicil
alpha-Aminobenzylpenicillin
ampicillanyl
ampicillin
anhydrous ampicillin
6
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1174253123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
7
CarboplatinapprovedPhase 4, Phase 2, Phase 3, Phase 1, Phase 0181241575-94-410339178, 498142, 38904, 38904, 498142
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
8
Miconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1291222916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
9
RopivacaineapprovedPhase 4, Phase 359084057-95-471273, 175805
Synonyms:
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
(S)-(−)-1-propyl-2',6'-pipecoloxylidide
(S)-ropivacaine
84057-95-4
98717-15-8
AC1L41QM
AC1L41QN
BIDD:GT0203
C07532
C17H26N2O.HCl
CHEBI:8890
CHEMBL1077896
CID175804
CID175805
CPD000469137
D08490
I14-176
L-N-n-propylpipecolic acid-2,6-xylidide
LS-113954
 
MLS001401363
MolPort-003-983-292
NCGC00164597-01
Naropin
Naropin (TN)
ROPIVACAINE HCl
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine Hydrochloride
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
SAM001246524
SMR000469137
ST51051452
ropivacaine monohydrochloride,
ropivacaine monohydrochloride, (S)-isomer
10
EpinephrineapprovedPhase 4, Phase 3, Phase 2, Phase 076851-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenaclick
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
Auvi-q
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine bitartrate
Epinephrine chloride
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr
Epipen Jr.
Epipen Jr. Auto-Injector
Epipen jr
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
 
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
Primatene Mist Refill
Prime Asthma Relief
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
11
Epoetin alfaapprovedPhase 4, Phase 3, Phase 2612113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
12
LidocaineapprovedPhase 4, Phase 3, Phase 2991137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Afterburn
Akten
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bikini Zone Medicated
Bikini Zone Medicated Creme
Bio-0767
Bio-scriptives Lidum
Bio-scriptives Lidum Hemorroidal (anorectal)
Bio-scriptives Lidum Topical Analgesic
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
Burn Relief Leader
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Comfortcaine
Cuivasil
Curacaine Transdermal Corporation
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
Derma Numb
DermaFlex
Desert Harvest Releveum
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Dr. Numb
Dr. Richs Numbing
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gigi Anesthetic Numbing
Gravocain
H-releve Hemorrhoidal
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
Hawaiian Tropic
Hush Anesthetic
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
LS-805
Lanabiotic
 
Laryng-o-jet
Leostesin
Lida-Mantle
Lidall
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine 4% Cream
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Hydrochloride
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocaine hydrochloride
Lidocainum
Lidocainum [INN-Latin]
Lidocare Mist
Lidocaton
Lidocream 4
Lidocream 5
Lidoderm
Lidoderm 5
Lidoject-1
Lidoject-2
Lifestyles Epic Male Genital Desensitizer
Lignocaine
Lignocainum
Lingocaine
Lmx4
Lmx5
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Numb Master Topical Anesthetic
Numb Nuts
Ocean Potion Instant Burn Relief Ice
Octocaine
Octocaine-100
Octocaine-50
Plum Smooth Plumb Numb Gelee
Premjact Male Desensitizer Pound International
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Recticare
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Simplicity Desensitizing
Simply Numb Endure
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Sole Serum
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Walgreens Aloe Vera Pain Relieving
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocaine-mpf
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zcaine Fast Acting Anesthetic
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
13
Propofolapproved, investigationalPhase 4, Phase 38532078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
14
Etidronic acidapprovedPhase 4, Phase 3407414-83-73305
Synonyms:
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphoshonic acid
(1-Hydroxyethylidene)diphosphonic acid
(1-hydroxy-1-phosphonoethyl)phosphonic acid
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(Hydroxyethylidene)diphosphonic acid
0-02-00-00171 (Beilstein Handbook Reference)
1,1,1-Ethanetriol diphosphonate
1-HYDROXY-1,1-DIPHOSPHONOETHANE
1-Hydroxy-1,1-diphosphonoethane
1-Hydroxyethane-1,1,-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene 1,1-diphosphonic acid
1-Hydroxyethylidene-1,1-biphosphonate
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1-Hydroxyethylidenediphosphonic acid
1-hydroxyethane 1,1-diphosphonic acid
1000SL
100511-44-2
103736-66-9
106908-76-3
129130-42-3
138360-84-6
14860-53-8 (tetra-potassium salt)
192526-55-9
2809-21-4
303177-33-5
51888-66-5
54342_ALDRICH
54342_FLUKA
66216-98-6
853028-38-3
85985-26-8
86159-18-4
AC1L1FMT
Acetodiphosphonic acid
Acide etidronique
Acide etidronique [INN-French]
Acido etidronico
Acido etidronico [INN-Spanish]
Acidum etidronicum
Acidum etidronicum [INN-Latin]
BPBio1_000997
BRN 1789291
BSPBio_000905
Bio-0708
C07736
CHEBI:170675
CHEBI:4907
CHEMBL871
 
CID3305
Cintichem Technetium 99m Hedspa
D02373
DB01077
Dequest 2010
Dequest 2015
Dequest Z 010
Didronel
Didronel IV
Diphosphonate (base)
EHDP
EINECS 220-552-8
Ethane-1-hydroxy-1,1-bisphosphonate
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidronate Disodium
Etidronate disodium
Etidronic acid
Etidronic acid (USAN/INN)
Etidronic acid [USAN:INN:BAN]
Etidronic acid monohydrate
Etidronsaeure
Etidronsäure
Ferrofos 510
H0587
H6773_ALDRICH
H6773_SIGMA
HEDP
HSDB 5898
Hydroxyethane-1,1-diphosphonic acid
Hydroxyethanediphosphonic acid
I14-1271
Jsp005415
LS-106637
MLS002207267
MLS002695948
MPI Stannous Diphosphonate
MolPort-001-786-542
NCGC00159352-02
NSC 227995
NSC227995
Osteoscan
Oxyethylidenediphosphonic acid
Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
Prestwick0_000863
Prestwick1_000863
Prestwick2_000863
Prestwick3_000863
RP 61
SMR000038750
SPBio_002826
STK721995
Turpinal SL
UNII-M2F465ROXU
ethane-1-hydroxy-1,1-bisphosphonic acid
etidronate
15
PertuzumabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0100145040-37-5, 380610-27-52540
Synonyms:
2C4 Antibody
380610-27-5
D05446
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MOAB2C4
Monoclonal Antibody 2C4
 
Omnitarg
Perjeta
Pertuzumab
Pertuzumab (USAN/INN)
Pertuzumab (genetical recombination)
Pertuzumab (genetical recombination) (JAN)
pertuzumab
rhuMAb 2C4
rhuMAb-2C4
16
imatinibapprovedPhase 4, Phase 2, Phase 1567152459-95-5644241, 5291
Synonyms:
112GI019
152459-95-5
1iep
1xbb
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide
AC-524
AC1L1K0Z
AKOS000280662
BIDD:GT0047
BRD-K92723993-066-02-9
Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)
CCRIS 9076
CGP 57148B
CGP57148
CGP57148B
CHEBI:45783
CHEMBL941
CID5291
Cgp 57148
D08066
DB00619
DB03261
EN002706
FT-0083542
Glamox
Glamox (TN)
 
Gleevec
Glivec
HMS2089D03
I01-1232
Imatinib
Imatinib (INN)
Imatinib Mesylate
Imatinib Methansulfonate
Imatinib [INN:BAN]
Imatinib free base
Imatinibum
Kinome_3724
LS-182208
LS-187106
MolPort-000-883-342
N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
NCGC00159456-02
NCGC00159456-03
NCGC00159456-04
NSC743414
STI
STI 571
STI-571
STI571
STK617705
UNII-BKJ8M8G5HI
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
imatinib
nchembio.117-comp23
nchembio.162-comp5
nchembio.282-comp6
nchembio.83-comp14
sti-571
17
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 01820216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
18
Pregabalinapproved, illicit, investigationalPhase 4, Phase 3, Phase 2327148553-50-85486971
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3-Isobutyl gaba
3-isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
CID5486971
 
D02716
DB00230
FT-0080911
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
19
LactuloseapprovedPhase 4894618-18-211333
Synonyms:
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
4-O-b-D-Galactopyranosyl-D-Fructofuranose
4-O-b-D-Galactopyranosyl-D-fructose
4-O-beta-D-Galactopyranosyl-D-Fructofuranose
4-O-beta-D-Galactopyranosyl-D-fructofuranose
4-O-beta-D-Galactopyranosyl-D-fructose
4-O-beta-delta-Galactopyranosyl-delta-Fructofuranose
4-O-beta-delta-Galactopyranosyl-delta-fructose
Bifiteral
Cephulac
 
Constulose
D-Lactulose
Enulose
Generlac
Kristalose
Lactulosa
Lactulose
Lactulosum
delta-Lactulose
lactulosa
lactulosum
20
GadobutrolapprovedPhase 4, Phase 347138071-82-615814656
Synonyms:
 
Gadavist
gadolinium(III) 2,2',2''-(10-((2R,3S )-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
21
Diazepamapproved, illicitPhase 4, Phase 2, Phase 192439-14-53016
Synonyms:
1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
11100-37-1
439-14-5
5-24-04-00300 (Beilstein Handbook Reference)
53320-84-6
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine
7-Chloro-1-methyl-5-3H-1,4-benzodiazepin-2(1H)-one
7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one
7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
A3662/0155188
AC-10561
AC1L1EZE
AKOS003367969
Alboral
Aliseum
Alupram
Amiprol
An-Ding
Ansilive
Ansiolin
Ansiolisina
Antenex
Anxicalm
Anxionil
Apaurin
Apo-Diazepam
Apo-diazepam
Apozepam
Armonil
Arzepam
Assival
Atensine
Atilen
Azedipamin
BIDD:GT0105
BIDD:PXR0158
BRD-K16508793-001-01-8
BRN 0754371
BSPBio_003279
Baogin
Bensedin
Benzopin
Best [Pharaceutical]
Betapam
Bialzepam
Britazepam
C06948
CB 4261
CCRIS 6009
CHEBI:49575
CHEMBL12
CID3016
CPD000058398
Calmaven
Calmocitene
Calmociteno
Calmod
Calmpose
Caudel
Centrazepam
Cercine
Ceregulart
Chuansuan
Condition
D-Pam
D00293
D003975
D0899_SIGMA
D9900_FLUKA
D9900_SIGMA
DAP
DB00829
DB07699
DEA No. 2765
DZP
Desconet
Desloneg
Diacepan
Diaceplex
Dialag
Dialar
Diapam
Diapax
Diapine
Diaquel
Diastat
Diastat (TN)
Diastat Acudial
Diatran
Diazapam
Diazem
Diazemuls
Diazemulus
Diazepam
Diazepam (JP15/USP/INN)
Diazepam Dak
Diazepam Desitin
Diazepam Elmu
Diazepam Fabra
Diazepam Intensol
Diazepam Nordic
Diazepam Rectubes
Diazepam Stada
Diazepam [USAN:INN:BAN:JAN]
Diazepam solution
Diazepam-Eurogenerics
Diazepam-Lipuro
Diazepam-ratiopharm
Diazepamu
Diazepamu [Polish]
Diazepamum
Diazepamum [INN-Latin]
Diazepan
Diazepan leo
Diazepin
Diazetard
Dienpax
Dipam
Dipaz
Dipezona
Disopam
DivK1c_000967
Dizac
Domalium
Doval
Drenian
Ducene
Duksen
Dupin
Duxen
E-Pam
EINECS 207-122-5
Elcion CR
Eridan
Euphorin P
Eurosan
Evacalm
Faustal
Faustan
Faustan,
Freudal
Frustan
Gewacalm
Gihitan
Gradual
Gubex
HMS2051N04
HMS503A15
HSDB 3057
I06-0194
IDI1_000967
Iazepam
 
Jinpanfan
KBio1_000967
KBio3_002780
KBioGR_001012
Kabivitrum
Kiatrium
Kratium
Kratium 2
LA 111
LA III
LA-111
LS-122
La-Iii
Lamra
Lembrol
Levium
Liberetas
Lizan
Lovium
MLS000759402
Mandro
Mandro-Zep
Mandrozep
Medipam
Mentalium
Metamidol
Methyl diazepinone
Methyldiazepinone
Methyldiazepinone (pharmaceutical)
Methyldiazepinone, pharmaceutical
Metil Gobanal
MolPort-001-729-114
Morosan
NCGC00178168-01
NINDS_000967
NSC 169897
NSC-77518
NSC169897
NSC77518
Nellium
Nerozen
Nervium
Neurolytril
Nivalen
Nixtensyn
Noan
Notense
Novazam
Novo-Dipam
Novodipam
Oprea1_126223
Ortopsique
Paceum
Pacitran
Paralium
Paranten
Parzam
Paxate
Paxel
Paxum
Placidox 10
Placidox 2
Placidox 5
Plidan
Pms-Diazepam
Pomin
Pro-Pam
ProPAM
Prozepam
Psychopax
Q-Pam
Q-Pam Relanium
Q-pam
Quetinil
Quiatril
Quievita
Radizepam
Relaminal
Relanium
Reliver
Renborin
Ro 5-2805
Ro 5-2807
Ruhsitus
S.A. R.L
S.a. r.l.
SAM001246536
SMR000058398
STK735517
Saromet
Sedapam
Sedipam
Seduksen
Seduxen
Serenack
Serenamin
Serenzin
Servizepam
Setonil
Sibazon
Sibazone
Sico Relax
Simasedan
Sipam
Solis
Sonacon
Spectrum3_001780
Spectrum4_000576
Spectrum5_001890
Stesolid
Stesolin
T-quil
Tensium
Tensopam
Tranimul
Trankinon
Tranqdyn
Tranquase
Tranquirit
Tranquo-Puren
Tranquo-Tablinen
Tranquo-puren
Tranquo-tablinen
Trazepam
UNII-Q3JTX2Q7TU
Umbrium
Unisedil
Usempax Ap
Usempax ap
Valaxona
Valeo
Valiquid
Valitran
Valium
Valium (TN)
Valium R
Valrelease
Valuzepam
Vanconin
Vatran
Vazen
Vazepam
Velium
Vival
Vivol
WLN: T67 GNV JN IHJ CG G1 KR
WY-3467
Winii
Wy 3467
ZINC00006427
Zepaxid
Zetran
Zipan
diazepam
e-Pam
nchembio.307-comp2
nchembio747-comp27
neurolytr il
22
ChlorhexidineapprovedPhase 436455-56-19552079, 2713
Synonyms:
1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide
1,6-Bis(5-(p-chlorophenyl)biguandino)hexane
1,6-Bis(p-chlorophenyldiguanido)hexane
1,6-Di(4'-chlorophenyldiguanido)hexane
1,6-Di(N-p-chlorophenyldiguanido)hexane
24798_FLUKA
282227_ALDRICH
348031_ALDRICH
4-12-00-01201 (Beilstein Handbook Reference)
55-56-1
AB00053427
AB1003159
AVAGARD
BPBio1_000272
BRN 2826432
BSPBio_000246
BSPBio_001977
Betasept
C06902
C22H30Cl2N10
CAS-55-56-1
CCRIS 9230
CHEBI:3614
CHEMBL790
CID9552079
Chlorhexidin
Chlorhexidin [Czech]
Chlorhexidine
Chlorhexidine (INN)
Chlorhexidine Base
Chlorhexidine Gluconate
Chlorhexidine [INN:BAN]
Chlorhexidine gluconate
Chlorhexidinum
Chlorhexidinum [INN-Latin]
Cloresidina
Cloresidina [DCIT]
Clorhexidina
Clorhexidina [INN-Spanish]
D07668
DB00878
Decanoylacetaldehyde Sodium Sulfide
Dentisept [veterinary]
Dentisept [veterinary] (TN)
DivK1c_000761
EINECS 200-238-7
Fimeil
HMS1568M08
HSDB 7196
Hexadol
Hibiclens
Hibispray
Hibistat
I06-0621
I14-0050
IDI1_000761
KBio1_000761
 
KBio2_000717
KBio2_003285
KBio2_005853
KBio3_001197
KBioGR_000774
KBioSS_000717
LS-43917
Lisium (*Dihydrochloride*)
MK-412A
MLS001332387
MLS001332388
MLS002154209
Merfen-incolore
Merfen-incolore (TN)
MolPort-002-541-741
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
NCGC00016246-01
NCGC00091025-01
NCGC00091025-02
NINDS_000761
NSC526936
Nolvasan
Nolvasan (*Diacetate*)
Novalsan
Oro-Clense
Paroex
Perichlor
Peridex
Periochip
Periogard
Prestwick0_000143
Prestwick1_000143
Prestwick2_000143
Prestwick3_000143
Prestwick_53
QTL1_000020
Rotersept
SMR000857146
SPBio_000210
SPBio_002185
STK089248
STOCK1S-18831
Savloclens
Savlon babycare
Sebidin A
Sodium Houttuyfonamide
Soretol
Spectrum2_000135
Spectrum3_000339
Spectrum4_000277
Spectrum5_001322
Spectrum_000237
Sterido
Sterilon
Superspray
Tubulicid
UNII-R4KO0DY52L
chlorhexidine
23
Toremifeneapproved, investigationalPhase 4, Phase 3, Phase 22589778-26-73005573
Synonyms:
(Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1)
2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC)
2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine
2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
89778-26-7
89778-27-8 (citrate (1:1))
98644-21-4
AC-1751
AC1MHJ33
Acapodene
BIDD:ER0222
BIDD:GT0211
BIDD:PXR0202
C08166
CCRIS 8745
CHEBI:9635
CHEMBL1655
CID3005573
D08620
DB00539
Estrimex
 
FC-1157a
Fareston
Farestone
GTX-006 (Acapodene)
GTx 006
GTx-006
HMS2090B22
LS-7729
MolPort-002-508-208
NCGC00160530-01
STK626445
STOCK6S-27411
Toremifene (INN)
Toremifene Base
Toremifene Citrate (1:1)
Toremifene [INN:BAN]
Toremifeno
Toremifeno [Spanish]
Toremifenum
Toremifenum [Latin]
UNII-7NFE54O27T
Z-Toremifene
toremifene
{2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine
24
Fulvestrantapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1157129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
Faslodex(ICI 182,780)
 
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
SID29215034
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
25
Pemetrexedapproved, investigationalPhase 4, Phase 1, Phase 2561150399-23-8446556, 60843
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
HSDB 7316
 
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY-231514
LY231514
LY231514 disodium
LYA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NCGC00167517-01
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed Disodium
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
SID50112739
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
nchembio.108-comp6
26
TriclosanapprovedPhase 4543380-34-55564
Synonyms:
1014 Foaming Antimicrobial
112099-35-1
164325-69-3
2,4,4'-Trichloro-2'-hydroxy diphenyl ether
2,4,4'-Trichloro-2'-hydroxydiphenyl ether
2-Hydroxy-2',4,4'-trichlorodiphenyl Ether
261921-78-2
3380-34-5
5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL
5-Chloro-2-(2,4-dichloro-phenoxy)-phenol
524190_ALDRICH
72779_FLUKA
72779_SIGMA
88032-08-0
AC-10667
AC1L1KMN
Acclaim
Action Chemical Antibac Clear
Aerogreen Antibac
Aerogreen Antibacterial
Allegheny Antibac
Altair Hand Care System Foam Anti-bacterial Hand
Anchor Foaming Mango
Anti-bacterial Blue Raspberry Hand
Anti-bacterial Bubble Gum Hand
Anti-bacterial Foaming
Anti-bacterial Fresh Aloe Hand
Anti-bacterial Lemon Drop Hand
Anti-bacterial Moisturizing Hand Pumpkin Caramel Latte
Anti-bacterial Strawberry Kiss Hand
Antibac Foam Wash
Antibac Foam Wash/aerogreen
Antibacterial
Antibacterial Amber Hand Soap
Antibacterial Bar
Antibacterial Body Wash
Antibacterial Body Wash Moisturizing
Antibacterial CUCUMBER MELON
Antibacterial Citrus Coconut
Antibacterial Citrus Fresh
Antibacterial FOAMING
Antibacterial FOR THE KITCHEN
Antibacterial FRESH PEAR
Antibacterial Foam Energizing Citrus
Antibacterial Foam Lavender Fragrance
Antibacterial Foaming
Antibacterial Foaming BERRY MEDLEY
Antibacterial Foaming COMPLETE
Antibacterial Foaming CRANBERRY
Antibacterial Foaming CUCUMBER MELON
Antibacterial Foaming Cucumber Melon
Antibacterial Foaming FRESH PEAR
Antibacterial Foaming GREEN TEA
Antibacterial Foaming Hand Cleanser
Antibacterial Foaming Hand Sp Lemongrass
Antibacterial Foaming Hand Wash Olive
Antibacterial Foaming ORIGINAL
Antibacterial Foaming PEAR
Antibacterial Foaming PEAR SCENT
Antibacterial Foaming PLUMERIA
Antibacterial Foaming POMEGRANATE
Antibacterial Foaming REFILL
Antibacterial Foamy Mango
Antibacterial Hand
Antibacterial Hand - Aloe Vera
Antibacterial Hand - Ocean Fresh Scent
Antibacterial Hand - Strawberry Pomegranate Scent
Antibacterial Hand -vanilla Brown Sugar
Antibacterial Hand Soap
Antibacterial Hand Soap FOR SENSITIVE SKIN
Antibacterial LIGHT MOISTURIZERS
Antibacterial LIGHT MOISTURIZERS REFILL
Antibacterial Liquid Energizing Citrus
Antibacterial Liquid Hand
Antibacterial Lotion Soap
Antibacterial MANDARIN
Antibacterial Pamegranate Apple
Antibacterial Passion Flower
Antibacterial Plum Foam
Antibacterial REFILL
Antibacterial SPARKLING MIST
Antibacterial SUNBLOSSOM
Antibacterial Skin Rain Forest Extract From Entiere
Antibacterial Spray
Antibacterial Wet Wipes
Antimicrobial
Antimicrobial Hand
Aplicare Physicians Antibacterial
Appeal Antibac
Appeal Antibacterial Hand Wash
Applaud
Apple Cider Antibacterial Foaming Hand Wash
Apple Spice Antibacterial Foaming Hand Wash
Aquasept
Aromafields Jasmine Scented Anti-bacterial Hand
Aromafields Jasmine Scented Antibacterial Hand Wash
Aromafields Lavender Scented Anti-bacterial Hand
Aromafields Lavender Scented Antibacterial Hand Wash
Aromafields Plumeria Scented Anti-bacterial Hand
Aromafields Plumeria Scented Antibacterial Hand Wash
Aromafields Tiger Lily Scented Anti-bacterial Hand
Aromafields Tiger Lily Scented Antibacterial Hand Wash
Asepso
Asept
Astound Antibac
Astound Antibacterial
Aterra Antibacterial Foaming Hand Wash
Aterra Antibacterial Hand Wash
Aurora ANTIBACTERIAL APPLE SUMMER BERRY
Aurora ANTIBACTERIAL BASIL KEY LIME
Aurora ANTIBACTERIAL COCONUT TROPICAL ISLAND
Aurora ANTIBACTERIAL JAPANESE FLOWER GARDEN
Aurora ANTIBACTERIAL VANILLA BROWN SUGAR
Autumn Medley Antibacterial Foaming Hand Wash
Avalon Premium French Milled
Avocado Antibacterial Hand Wash
Avocado Lime Antibacterial Foaming Hand Wash
Avocado Olive Antibacterial Foaming Hand Wash
BRN 2057142
Bacti-foam
Bacti-free Tm Antibacterial Hand
Bacti-stat
Bacti-stat Ae
Bebelle For Kids Antibacterial Hand
Because Antibacterial Hand Jafra
Ben E. Keith Antibacterial Hand Cleaner
Ben E. Keith Foaming Antibacterial Hand Cleaner
Blueberry Antibacterial Hand Wash
Blueberry Dream Antibacterial Hand Wash
Body Essence Raspberry Antibacterial
Body Wash
Body Wash Clear Spring
Bodycology Brown Sugar Vanilla
Bodycology Cherry Blossom
Bodycology Coconut Lime
Bodycology Cucumber Melon
Bodycology Peppermint Sugar Anti-bacterial Scrubbing Hand Soap
Bodycology Sparkling Cranberry Anti-bacterial Scrubbing Hand Soap
Bodycology White Gardenia
Bodycology White Gardenia Anti-bacterial Foaming Hand Soap
Bodycology White Gardenia Anti-bacterial Scrubbing Hand Soap
Bright Solutions Antibac
Bright Solutions Antibacterial
C12059
C12H7Cl3O2
CCRIS 9253
CH 3565
CH-3565
CHEBI:164200
CHEMBL849
CID5564
CPD0-1227
CPD000471847
Candy Apple Anti Bacterial Foaming Hand
Care One ANTIBACTERIAL PEPPERMINT SWIRL
Care One ANTIBACTERIAL RUM RAISIN
Care One ANTIBACTERIAL SNOW KISSED PEAR
Care One ANTIBACTERIAL TANGERINE SPICE
Care One Antibacterial Foaming Hand Soap Green Tea
Care One CREAMY COCONUT
Care One LEMON VERBENA
Care One PEPPERMINT SWIRL
Care One PINE
Care One PUMPKIN PIE
Care One SUN KISSED PEAR
Care One VANILLA APPLE BLOSSOM
Care One VANILLA BEAN
Careone ANTIBACTERIAL
Careone APPLE BERRY
Careone COUNTRY APPLE
Careone LIME BASIL
Careone TAHITIAN COCONUT
Careone VANILLA BROWN SUGAR
Caribbean Escape Anti Bacterial Foaming Hand
Caswell No. 186A
Cetaphil Gentle Cleansing Antibacterial Bar
Chemstar Antibac
Cinnamon Clove Antibacterial Foaming Hand Wash
Cinnamon Sticks Antibacterial Foaming Hand Wash
Citrus Basil Antibacterial Cleansing Hand Wash
Citrus Basil Antibacterial Creamy Hand Wash
Citrus Basil Antibacterial Foaming Hand Wash
Citrus Basil Antibacterial Hand Wash
Citrus Breeze Antibacterial Foaming Hand Wash
Citrus Burst Antibacterial Cleansing Hand Wash
Citrus Burst Antibacterial Foaming Hand Wash
Citrus Burst Antibacterial Hand Wash
Clean Force
Clean Strike
Clear Antibacterial Hand
Clearasil Daily Face Wash
Clearskin Pore Penetrating Cleanser
Cliniclean
Cloxifenol
Cloxifenolum
Coconut Antibacterial Creamy Hand Wash
Cool Plum Antibacterial foaming hand
Coral
Cotton Candy Anti Bacterial Foaming Hand
Country Apple Antibacterial Foaming Hand Wash
Cranberry Antibacterial Foaming Hand Wash
Cranberry Cream Antibacterial Hand Wash
Cranberry Orange Antibacterial Foaming Hand Wash
Cranberry Spice Antibacterial Foaming Hand Wash
Creamy Peach Antibacterial Foaming Hand Wash
Cucumber Lime Antibacterial Foaming Hand Wash
Cucumber Melon Antibacterial Foaming Hand Wash
Cv Medicated
Cvs Antibacterial Foaming Kitchen
Cvs Pharmacy
Cvs Pharmacy ANTIBACTERIAL
Cvs Pharmacy CLEAN ANTIBACTERIAL
Cvs Pharmacy MANDARIN CITRUS
Cvs Pharmacy PEAR WHITE TEA
Cvs Phramacy Antibacterial Melon
D014260
D06226
DB08604
DP-300
Dalan Golden Tropics Antibacterial Deodorant
Dalan Ocean Breeze Antibacterial Deodorant
Dalan Spring Freshness Antibacterial Deodorant
Dawn Classic
Dawn Ultra Concentrated Apple Blossom
Dawn Ultra Concentrated Orange
Dawnmist Antibacterial
Dawnmist Deodorant
Dawnmist Deodorant Bar No. 1 1/2
Dawnmist Deodorant Bar No. 1/2
Dawnmist Deodorant Bar No. 3
Dawnmist Deodorant Bar No. 3/4
Dawnmist Deodorant Bar No. 5
Dawnmist Deodorant Bar Soap No. 1
Deb Gold
Deb Med Antibacterial Foam Hand Wash
Deb Med Antimicrobial Foaming Hand Wash
Deb Med Antimicrobial Foaming Hand Wash Cucumber Aloe
Deb Med Antimicrobial Foaming Hand Wash Fragrance Free Dye Free
Deb Med Antimicrobial Foaming Hand Wash Fresh Grapefruit
Debmed Antimicrobial
Delta Foremost Antibac
Deluxe All-purpose
Deluxe Dish Detergent
Derma-glove
Dermacare
Dermacen Antimicrobial-t Hand
Dermacen Foaming Antimicrobial-t Hand
Dermaprot TRICLOTREX-B
Dermoplus Medicated
Dermtek Brand of Triclosan
Dewberry Burst Antibacterial Foaming Hand Wash
Dg Body ANTIBACTERIAL
Dhc Hand
Dial Complete Antibacterial Foaming Hand Wash Hello Kitty
Dial Complete Antibacterial Foaming Hand Washholiday Line Holiday Line holiday line
Dial Complete Antibacterial Foaming Hand Washkitchen Crisp Limkitchen Crisp Lim kitchen crisp lime
Dial Mountain Fresh Antibacterial Body Wash
Dial Tropical Escape Antibacterial Body Wash
Digiclean
Digiclean Slim-line
Dignity Antibacterial
Dreumex Omnicare
Dt Antibacterial Foaming Hand Wash
Dt Antibacterial Hand
EINECS 222-182-2
EPA Pesticide Chemical Code 054901
Eco-clean Elite
Ecocare 250
Ecolab
Ecolab Digiclean
Ecolab Facilipro
Ecosave Japanese Cherry Blossom Soap Antibacterial Hand Soap
Ecosave Lavender Antibacterial Hand Soap
Endure 100
Endure 200
Endure 250
Enmotion High Frequency Antimicrobial Foam Handwash
Equaline
Equaline Liquid
Equate ANTIBACTERIAL FOAMING
Equate SPRING SHOWERS ANTIBACTERIAL
Essential Everyday Orange Scent
Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl
Exchange Select Ultra Citrus Scent
Exuviance Moisturizing Antibacterial Facial Cleanser
Family Dollar Antibacterial
Family Dollar Antibacterial Hand
Family Dollar Foaming Antibacterial Hand Wash
First Force
First Mark Antibacterial Hand Wash
First Mark Foam Antimicrobial Hand Cleaner
Foam Antibacterial Hand Wash
Foaming Antibacterial
Foaming Antibacterial Cucumber Melon
Foaming Antibacterial PLUMERIA
Foaming Antibacterial Pear
Foaming Antimicrobial
Foaming Hand Wash
Foaming Hand Wash Antibacterial
Foamy Mango
Forest Fresh
Freds ANTIBACTERIAL FRESH PEAR
Fresh Blueberry Antibacterial Foaming Hand Wash
Fresh Citrus
Fresh Herbs Antibacterial Foaming Hand Wash
Fresh Herbs Antibacterial Hand Wash
Fresh Lemon Antibacterial Foaming Hand Wash
Fresh Lemon Antibacterial Hand Wash
Fresh Lime Antibacterial Foaming Hand Wash
Fresh Linen Antibacterial Foaming Hand Wash
Fresh Pear Foaming hand
Fresh Pearsilk Antibacterial Foaming Hand
Fresh Picked Strawberries Anti Bacterial Foaming Hand
Freshands
Freshscent Anti-bacterial
Fruit Medley Antibacterial Foaming Hand Wash
Fuller Antibacterial Hand
Gain Ultra Lemon Zest
Gentle Rain Antibacterial
Germasidol
Germicida Antimicrobial
Ginger Blossom Antibacterial Foaming Hand Wash
GlaxoSmithKline Brand of Triclosan
Gojo Antibacterial
Gold Antibacterial Hand Safety
Golden Pear Antibacterial Cleansing Hand Wash
Golden Pear Antibacterial Foaming Hand Wash
Golden Pear Antibacterial Foaming Handwash
Grape Vineyard Antibacterial Hand Wash
Great Value Ultra Concentrated Green Apple Scent
Great Value Ultra Concentrated Orange Scent
HMS2093L17
HSDB 7194
Hand
Hand Antibacterial Premium
Hand Cleanse
Hand Cleanse - Ocean Fresh
Hand Cleanse - Strawberry Pomegranate
Hand Cleanse Refill
Hand Essentials Antibacterial
Hand Guard Foaming Antimicrobial
Hand Kleen Foaming Antibacterial Hand
Hand Kleen Golden Touch Antibacterial Hand Cleanser
Hand Kleen Premium Antibacterial Hand
Hand Kleen Southern Orchardantibacterial Han Antibacterial Hand Cleanser
Handsoap
Handtastic Foamy Mango
Harris Teeter ANTIBACTERIAL
Harris Teeter Antibacterial
Harris Teeter Foaming
Harvest Grape Antibacterial Foaming Hand Wash
Haunted Halloween Antibacterial Foaming Hand Wash
Healing Waters Cucumber Mint Antibacterial Hand Soap
Healing Waters Mandarin Vanilla Antibacterial Hand Soap
Healing Waters Sweet Pea Antibacterial Hand Soap
Health Smart Antibacterial Cucumber Melon
Health Smart Antibacterial Lavender Chamomile
Health Smart Antibacterial Original
Health Smart Antibacterial Spring Rain
Health Smart Antibacterial Sweet Pea Orchid
Health Stat
Health-stat Foam
Healthy Accents Antibacterial Body Wash Spring Fresh
High Five
Hill Country Essentials
 
Hill Country Essentials ANTIBACTERIAL
Hill Country Essentials Antibacterial
Hill Country Essentials Antibacterial Foaming
Hillyard Golden Antimicrobial
Hillyard Golden Antimicrobial Foaming
Holiday Elegance
Holiday Elegancefrosted Gingerbre Frosted Gingerbread
Holiday Elegancefrosted Gingerbrefrosted Gingerbre Frosted Gingerbread
Holiday Elegancepeppermint Twist Peppermint Twist Peppermint Twist
Holiday Treats Antibacterial Foaming Hand Wash
Home 360 Ultra Dish Detergent Green Apple Scent
Honey Almond Antibacterial Foaming Hand Wash
Honey Apple Antibacterial Foaming Hand Wash
Honey Vanilla Antibacterial Foaming Hand Wash
Honey Vanilla Antibacterial Hand Wash
Husky 575 Foaming Antiseptic Hand Cleaner
I01-2897
IN1424
Iced Vanilla Antibacterial Foaming Hand Wash
Image Essentials
Image Essentials ANTIBACTERIAL HAND GOLD
Image Essentials Antibacterial
Image Essentials Antibacterial Gold
Image Essentials SPRING FRESH
Irgasan
Irgasan DP 300
Irgasan DP300
Island Banana Antibacterial Foaming Hand Wash
Island Blossom Antibacterial Foaming Hand Wash
Island Breeze Antibacterial Foaming Hand Wash
Jasmine Mint Antibacterial Foaming Hand Wash
Johnson & Johnson Brand of Triclosan
Joy Non-ultra
Joy Ultra Orange
Juicy Orange Antibacterial Foaming Hand Wash
Karesse
Kay QSR
Keystone
Keystone Antibacterial
Kindest Kare Antimicrobial Foaming Handwash Healthcare Personnel Handwash
Kitchen Citrus foaming hand
Kiwi Crate Liquid Hand
Kiwi Lime Antibacterial Foaming Hand Wash
Kiwi Strawberry Antibacterial Foaming Hand Wash
Kiwi Strawberry Foaming Hand Wash
Kleenex Antibacterial Skin Cleanser
LS-67854
Lavender Antibacterial Foaming Hand Wash
Lavender Sage Antibacterial Foaming Hand Wash
Le Techniq Antibacterial VANILLA BROWN SUGAR
Le Techniq FOAMING ANTIBACTERIAL HAND
Le Techniq MORNING MIST ANTIBACTERIAL HAND
Le Techniq PEAR
Le Techniq SPRING FRESH
Lemon Basil Antibacterial Foaming Hand Wash
Lemon Drop Antibacterial Hand Wash
Lemon Fresh Antibacterial Foaming Hand Wash
Lemon Verbeba Antibacterial Foaming Hand Wash
Lemon Verbena Antibacterial Foaming Hand Wash
Lemon Verbena Antibacterial Hand Wash
Lemon Zest Antibacterial Foaming Hand Wash
Lemon Zest Antibacterial Hand
Lemongrass Tea Antibacterial Foaming Hand Wash
Lever 2000 Antibacterial
Lexol 300
Liquid Hand Cleanse
Lornamead Yardley
Lucky Antibacterial Deodorant
Lucky Antibacterial Hand Soap Supersoft
Lucky Supersoft Antibacterial Hand
Luxury
Lysol I.c. Antimicrobial
Lysol No Touch
MLS001066347
MLS001074876
MLS001335937
MLS001335938
Macaroon Antibacterial Foaming Hand Wash
Mandarin Nectar Antibacterial Foaming Hand Wash
Mandarin Nectar Antibacterial Foaming Handwash
Mandarin Orange Antibacterial Foaming Hand Wash
Mandarin Orange Antibacterial Hand
Manderin Orange Antibacterial Foaming Hand Wash
Mango Madness Anti Bacterial Foaming Hand
Mango Spice Antibacterial Foaming Handwash
Manusept
Market Basket Ultra
Mckesson Antimicrobial Hand
Medicated Soft N Sure Healthcare Personnel Handwash
Meijer ANTIBACTERIAL FOAMING
Microshield T
Mischievous Orange Antibacterial Foaming Hand Wash
Moist Sure
Moisturizing Anti-bacterial Hand Soap
MolPort-003-666-702
Mulling Spices Antibacterial Foaming Hand Wash
My Essentials Citrus Scent
Mystic
NCGC00159417-02
NCGC00159417-03
NCGC00159417-04
Natural Concept Body Wash Spring Breeze
Natural Extensions Antibacterial Foaming Hand Wash
Natural Extensions Antibacterial Liquid Hand Wash
Naturals Antibacterial Liquid Soap Vanilla
Neostrata Antibacterial Facial Cleanser
Noxzema Bacteria Fighting Cleanser
Noxzema Triple Clean
Nu Skin Antibacterial Body Cleansing
Ocean Breeze Antibacterial Foaming Hand Wash
Oil Free Foaming Facial Cleanser
Olive Leaf Antibacterial Cleansing Hand Wash
Olive Leaf Antibacterial Creamy Hand Wash
Olive Leaf Antibacterial Foaming Hand Wash
Olive Oil Antibacterial Foaming Hand Wash
Optisource Foam Antibacterial Skin Cleanser
Orange Bliss Antibacterial Foaming Hand Wash
Orange Blossom Antibacterial Foaming Hand Wash
Orange Cinnamon Antibacterial Foaming Hand Wash
Orange Clove Antibacterial Foaming Hand Wash
Orchid
Orchid By H E B VANILLA BROWN SUGAR
Original Antibacterial Foaming Hand Source
Original Antibacterial Foaming hand
Oxy Skin Wash
Pacific Anti-bacterial Hand Cleanse Blueberry Essence
Pacific Anti-bacterial Hand Cleanse Kiwi Essence
Pacific Anti-bacterial Hand Cleanse Peach Essence
Pacific Anti-bacterial Hand Cleanse Strawberry Essence
Pacific Garden Antibacterial Foam Soothing Lavender
Pacific Garden Antimicrobial, Fragrance Free, Dye Free
Pacific Garden Antimicrobial, Pacific Citrus, Mandarin
Palmers Skin Success
Panache
Panache Antibacterial Body Wash
Panrosa Antibacterial Hand
Panrosa Green Apple Scented Hand
Panrosa Honey Scented Hand
Panrosa Lavender Scented Hand
Panrosa Rose Scented Hand
Papaya Mango Antibacterial Foaming Hand Wash
Passion Flower Antibacterial Foaming Hand Wash
Pear Barlet Antibacterial Hand
Perfect Purity Antibacterial Gold
Personal Care Antibacterial Foaming Hand Wash
Personal Care Antibacterial Hand
Personal Care Antibacterial Hand - Fresh Melon
Personal Care Antibacterial Hand - Fresh Peach
Personal Care Antibacterial Hand - Raspberry
Personal Care Oil Free Foaming Facial Cleanser
Pharmachem Brand of Triclosan
Pineapple Orange Antibacterial Foaming Hand Wash
Pineapple Pear Antibacterial Foaming Handwash
Pink Peony Antibacterial Foaming Hand Wash
Pioneer Antibac
Pomegranate Antibacterial Foaming Hand Wash
Pomegranate Orange Antibacterial Foaming Hand Wash
Pomegranate Spice Antibacterial Hand Wash
Powerhouse Fresh Scent Ultra Dish
Prevens
Price Chopper PUMPKIN SPICE ANTIBACTERIAL FOAMING
Pro Advantage Antibacterial
Problend Antibacterial Foam
Procter & Gamble Brand of Triclosan
Proforce Commercial Products
Proformance Antibacterial
Proformance Series Antibacterial
Protex Balance antibacterial liquid hand soap
Protex antibacterial
Provon Antibacterial Foam Handwash
Publix Ultradish Detergent
Publix Ultradish Detergent Green Apple Scent
Pumpkin Seeds Antibacterial Foaming Hand Wash
Pumpkin Spice Antibacterial Foaming Hand Wash
Pureforce
Purgo Satin Foam
Purgo Ultra
Purgo Ultra Foam
Puritan
Quiksan
Reckitt Brand of Triclosan
Red Apple Antibacterial Hand
Reeva Antibacterial Green Apple
Renewal
Rite Aid
Rite Aid Antibacterial
Rite Aid Foaming Hand
Rite Aid Liquid
Rite Aid Renewal
Rite Aid Renewal ANTIBACTERIAL
Rite Aid Renewal ANTIBACTERIAL CLEAR SPRING
Rite Aid Renewal CLEAR SPRING
Rite Aid Renewal PEAR
Rite Aid Renewal WHITE TEA
Roccos Old School Tattoo Balm Anti Bacterial Wash
Royal Antibacterial Orange Berry Hand Cleanse
Royal Antibacterial Passion Plum Hand Cleanse
Royal Antibacterial Raspberry Hand Cleanse
Royal Antibacterial Tropical Fruit Hand Cleanse
S00100
SAM002554907
SBB058565
SMR000471847
SSL Brand of Triclosan
Safeguard
Safeway
Safeway Care REFILL
Safeway Home Lemon Scent
Safeway Home Orange Scent
Sandy Beaches Antibacterial Foaming Hand Wash
Sanisuds Foam Antibacterial Hand
Sanitex Mvp Foam Anti-bacterial
Sapoderm
Satin Pink
Sbs Ultragreen
Sbs Ultrapink
Scott Antibacterial
Scott Clear Antibacterial Skin Cleanser
Sea Breeze Antibacterial Foaming Hand Wash
Secure Antibac
Sentry Antibac
Servo-stat T
Servo-stat T Foam
Servo-stat Te
Shop Rite Ultra So-soft
Shopko Antibacterial Deep Cleansing Hand
Shopko Antibacterial Foaming Hand Cleanser
Shopko Antibacterial Foaming Hand Sanitizer
Silk Antibacterial Foaming Hand
Silk Antibacterial Foaming Hand Fresh Pear
Silk Antibacterial Foaming Hand Original
Simple Pleasures antibacterial foaming hand
Simple Pleasures antibacterial hand
Simply Right ANTIBACTERIAL
Simply Right Body Care
Simply Right Body Care ANTIBACTERIAL
Simply Right Body Care SPARKLING MIST
Simply Right SPARKLING MIST
Skintegrity Antibacterial Hand Amber
Skintegrity Antibacterial Hand Blue
Skintegrity Antibacterial Hand Clear
Skintegrity Antibacterial Hand Foaming
Snow Drop Antibacterial Foaming Hand Wash
Soft Care Antiseptic Skin Cleanser Ii
Soft Care Foam Antibacterial Hand Soap
Soft Care Foam Select Antibacterial Hand
Soft Care Foam Select Antibacterial Triclosan
Soft Care Foaming Antibacterial Hand
Soft Care Neutra Germ Antibacterial
Soft Care Neutra Germ Fragrance Free Antibacterial
Softone Luxury Foam Antibacterial Skin Cleanser
Softsoap ANTIBACTERIAL HAND
Softsoap Antibacterial
Source Antibacterial Foaming Hand Original
Spa Originals Antibacterial Gold Hand
Spasoap Liquid Antibacterial
Spatherapy
Spiced Cider Antibacterial Foaming Hand Wash
Spiced Pumpkin Antibacterial Foaming Hand Wash
Spooky Sugar Cookie Antibacterial Foaming Hand Wash
Ster Zac Bath Concentrate
Ster-Zac Bath Concentrate
SterZac Bath Concentrate
Stoko Refresh
Stoko Refresh Food Handler Foam
Stri-Dex Cleansing Bar
Stri-Dex Face Wash
Stri-Dex cleansing bar (TN)
Studio 35 SPRING MORNING
Sugar Cookie Antibacterial Foaming Hand Wash
Sugar Cookie Antibacterial Hand Wash
Summer Berry Antibacterial Foaming Hand Wash
Summer Bouquet Antibacterial Foaming Hand Wash
Summer Breeze Antibacterial Foaming Hand Wash
Summer Citrus Antibacterial Foaming Hand Wash
Sun Blossom Antibacterial Foaming Hand Wash
Sweet Fig Antibacterial Foaming Hand Wash
Sweet Fig Antibacterial Hand Wash
Sweet Golden Pear Antibacterial Foaming Hand Wash
Sweet Golden Pear Antibacterial Hand Wash
Sweet Honey Antibacterial Hand Wash
Sweet Olive Leaf Antibacterial Foaming Hand Wash
Sweet Papaya Antibacterial Foaming Hand Wash
Sweet Peaches Antibacterial Foaming Hand Wash
Sweet Pear Antibacterial Foaming Hand Wash
Sweet Red Apple Antibacterial Foaming Hand Wash
TCL
TL8002539
Tc Enrichedfoam Antibacterial
Tc Enrichedlotion Antibacterial Hand Wash
Tc Spraysoap
Tersaseptic
Thera Rx
Therazcream
Topcare ANTIBACTERIAL FRESH PEAR
Topcare Antibacterial Foaming
Topcare MANDARIN
Topco ANTIBACTERIAL
Tork Premium
Tork Premium Antibacterial
Trans Canaderm Brand of Triclosan
Trick Or Treat Antibacterial Foaming Hand Wash
Triclonex T2
Triclosan
Triclosan (USP/INN)
Triclosan Pharmachem Brand
Triclosan Reckitt Brand
Triclosan [USAN:BAN:INN]
Triclosanum
Triclosanum [INN-Latin]
Triclotrex-b ANTIBACTERIAL
Triclotrex-b ANTIBACTERIAL (NEUTRAL)
Trisan
Tuscan Lemon Antibacterial Foaming Hand Wash
Tuscan Lemon Antibacterial Hand Wash
UNII-4NM5039Y5X
Ulta Fresh Spice Anti-bacterial Deep Cleansing
Ulta Freshwater Mist Anti-bacterial Deep Cleansing
Ulta Freshwater Mist Anti-bacterial Gentle Foaming
Ulta Lavender Woods Anti-bacterial Deep Cleansing
Ulta Lavender Woods Anti-bacterial Gentle Foaming
Ulta Mandarin Mint Anti-bacterial Deep Cleansing
Ulta Mandarin Mint Anti-bacterial Gentle Foaming
Ulta Nectarine Spice Anti-bacterial Deep Cleansing
Ulta Nectarine Spice Anti-bacterial Gentle Foaming
Ulta Pomegranate Lime Anti-bacterial Deep Cleansing
Ulta Pomegranate Lime Anti-bacterial Gentle Foaming
Ulta Red Raspberry Anti-bacterial Deep Cleansing
Ulta Sparkling Lemon Anti-bacterial Deep Cleansing
Ulta Sparkling Lemon Anti-bacterial Gentle Foaming
Ulta Vanilla Sugar Anti-bacterial Deep Cleansing
Ulta Vanilla Sugar Anti-bacterial Gentle Foaming
Ultragreen Antibacterial
United Lab Antibac
Up (and) Up Green Apple Scent
Vanilla Cream Antibacterial Hand Wash
Vanilla Cupcake Anti Bacterial Foaming Hand
Vanilla Honey Antibacterial Foaming Hand Wash
Vineyard Antibacterial Foaming Hand Wash
Vineyard Grape Antibacterial Hand Wash
Wegmans
Wegmans ANTIBACTERIAL
Wegmans Antibacterial Cucumber Melon
Wegmans Orange Scent
Wegmans Ultra Dishwashing Orange Scent
Whiskcare 387
Wild Strawberry Antibacterial Hand Wash
Witchs Brew Antibacterial Foaming Hand Wash
Xtracare Antibacterial Hand Cleanse Fresh Citrus
Xtracare Antibacterial Hand Cleanse Mountain Spring
Xtracare Antibacterial Hand Cleanse Original
Xtracare Antibacterial Hand Cleanse Strawberry Pomegranate
Xtracare Foaming Facial Cleanser
Zep Acclaim
Zep Anti-bacterial Foaming Hand Cleaner
Zep Applaud Hand Cleaner
Zep Aspen
Zep Blue Sky Foaming
Zep Cherry Creme
Zep Commercial Antibacterial Pear
Zep Mango Foaming
Zep Pear Anti-bacterial
Zep Professional Healthcare Worker
Zep Professional Mild Antimicrobial Hand Cleaner
Zep Professional Tranquil Meadows
Zep Professional Z-verdant Foaming
Zep Tranquil Meadows
27
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11742159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
28
PaclitaxelapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0250533069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
29
Nitrous oxideapprovedPhase 4, Phase 313910024-97-2948
Synonyms:
00583_FLUKA
10024-97-2
126386-65-0
129451-49-6
130835-71-1
147527-07-9
175876-44-5
295590_ALDRICH
794457-85-5
847968-13-2
850203-00-8
AC1L1ADZ
C00887
CCRIS 1225
CHEBI:17045
CHEMBL1234579
CID948
D00102
D009609
Diazyne 1-oxide
Dinitrogen monoxide
Dinitrogen oxide
Distickstoffmonoxid
E942
EINECS 233-032-0
FEMA 2779
FEMA No. 2779
Factitious air
Gas, Laughing
Gas, laughing
Gaz hilarant
HSDB 504
Hyponitrous acid anhydride
LS-7622
Lachgas
Laughing gas
N2O
NITROUS-OXIDE
NNO
 
Nitral
Nitrogen hypoxide
Nitrogen monoxide
Nitrogen oxide (N2O)
Nitrogen protoxide
Nitrogenium oxydulatum
Nitrous Oxide
Nitrous oxide
Nitrous oxide (JP15/USP)
Nitrous oxide (TN)
Nitrous oxide [Anaesthetics, volatile]
Nitrous oxide [JAN]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide [anaesthetics, volatile]
Nitrous oxide [jan]
Nitrous oxide, JAN, USAN
Nitrous oxide, compressed
Nitrous oxide, refrigerated liquid
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous-oxide
Oxide, Nitrous
Oxide, nitrous
Oxido nitroso
Oxido nitroso [Spanish]
Oxidodinitrogen(N--N)
Oxyde nitreux
Protoxyde d'azote [French]
Stickdioxyd
Stickdioxyd [German]
Stickstoff(I)-oxid
UN1070
UN2201
gaz hilarant
nitrogenium oxydulatum
nitrous oxide
oxidodinitrogen(N--N)
oxyde nitreux
protoxyde d'azote
30
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1243715663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
31
SevofluraneapprovedPhase 4, Phase 338128523-86-65206
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
BRN 2041023
Bax 3084
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
MR6S4
 
MR_6S4
MolPort-001-775-746
NCGC00167421-01
PC4681
Sevofluran
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
UNII-38LVP0K73A
Ultane
Ultane (TN)
ZINC01530810
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
sevoflurane
32
MentholapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 017482216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
999 Itch Relief
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
Absorbine Back Therapeutic Pain Relief
Absorbine Jr
Absorbine Jr Ultra Strength Pain Relieving
Absorbine Jr.
Absorbine Jr. Back
Algomend Pain Relief
Alhua Huogan Pain Relieving Patch
Aloemint Skin Aid
Amar Ice
Analgesic
Anc Neverpain External Analgesic
Anti Itch
Army Health Pain Reliever
Arthri-support
Arthri-zen Relief
Arthripain Relief
Arthritis Relief
Aspercreme Heat
Aspercreme Max No Mess Roll On
Assured Cold N Hot Pain Relief Menthol
Assured Extra Strength Cold N Hot
Assured Ice Cold Topical Analgesic
Assured Muscle Rub
Assured Pain Relief Hot Menthol
Atopalm Pain Relieving
Aurorae Healing Pain Relieving Roll-on
Avapta
Avedana Pain Relieving Roll On
Avedana Pain-relieving
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
Babyganics Cold Relief Chest Rub
Barox
Barox BODY CARE MASSAGE
Barox Body Care Massage Relax Refresh Revital
Being Well Extra Strength Menthol Heat
Bengay Ultra Strength Large Size
Bengay Ultra Strength Pain Relieving Large Size
Bengay Ultra Strength Pain Relieving Regular Size
Bengay Ultra Strength Regular Size
Bengay Vanishing Scent
Bengay Zero Degrees Menthol Pain Relieving
Bentasil SUGAR FREE BLACKCURRANT SOFT Texture
Bentasil SUGAR FREE CHERRY SOFT Texture
Bentasil SUGAR FREE HONEY LEMON SOFT Texture
Berri-freez
Besthealth Cherry
Besthealth Cough Suppressant Sugar Free Black Cherry Flavor
Besthealth Cough Suppressant Sugar Free Honey Lemon Flavor
Besthealth Honey Lemon
Besthealth Menthol
Bio 2 Brazilian Heat Brazilian Heat
Bio-scriptives Extreme Pr
Bioblast Pain Relief
Bioflexor
Biofreeze
Biofreeze Colorless
Biofreeze Colorless Roll-on
Biofreeze Roll-on
Biorelief Ice Pain Relieving
Blistex Ivarest Medicated Poison Ivy Cleansing Foam
Blue Gel Pain Relieving
Blue Ice
Blue Ice Analgesic
Blue Ice Analgesic Gel
Blue Ice Pain Relieving
Body
Budpack Muscle Rub
Budpak Muscle Rub
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Canker Complete Canker Sore Relief
Caswell No. 540
Celadrin
Cepacol Sore Throat From Post Nasal Drip
Cepacol Sore Throat Regular Strength
Ching Wan Hung Soothing Herbal Balm
Choice Personal Care Theraputic Blue Ice
Cold Hot Patch
Cold Spot Point Relief
Coldaid
Cool N Heat Patch For Back Extra Strength
Coralite Extra Strength Menthol Pain Relief Sleeve - Knee
Coralite Extra Strength Menthol Pain Relief Sleeve - Wrist
Coralite Pain Relief
Counteract Cough Drops Honey Lemon
Counteract Cough Drops Orchard Cherry
Cryogel Island Rain Natural Pain Relieving Vitaminerals
Cvs Cold Hot Medicated
Cvs Soothing Itch Relief
Cvs Sore Muscle Rub Vanishing Scent
Cvs Therapeutic Menthol Gel
Cvs Therapeutic Menthol Pain Reliever
Cvs Tropical Citrus Cough
Cvs Ultra Strength Pain Relieving
Cvs Vanishing Scent Muscle Rub
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
Dg Health Extra Strength Medicated
Dg Health Pain Relieving
Dg Ice Cold Analgesic
Diapedic Foot Treatment
DivK1c_000820
Dorflex Icy Hot Flexible, Large
Dorflex Icy Hot Flexible, Small
Dorflex Icy Hot Flexible, XL
Dr. Blue
Dt Ice Cold Analgesic
Dual Action Cherry Cough Suppressant Oral Anesthetic
Dynafreeze
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
Easy
Eb301ap Pain Relief
Eb301ct Bruise Pain Relief
Eb302 Arthritis Relief
Ecolyptus Pain Relieving Muscle Rub
Efac Pain Relieving
Elgin Pain Relief
Equaline Blue Ice Pain Relieving
Equate Menthol Extra Strength
Eros Iron Man
Eucalyptamint
Eucerin Calming Itch Relief Treatment
Extra Strength Cold N Hot Pain Relief Medicated
Extra Strength Pain Relief Therapy
Extra Strength Stopain Cold Pain Relieving
Extra Strength Stopain Cold Pain Relieving Roll On
FEMA No. 2665
Family Care Maximum Strength Medicated Anti Itch
Fast Freeze
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
Flexall Pain Relieving
Flexgen
Fluaid
Foot Works Achy Foot Massager Pain Relieving
Gold Bond Foot Extra Strength
Gold Bond Medicated Foot
Gold Bond Pain Relieving Foot
Gold Bond Pain Relieving Foot Roll On
Green Bamboo
Green Guard Cough Drop Relief
HMS1922G13
HMS2092L14
HMS502I22
HSDB 5662
HSDB 593
Halls Apple Cider
Halls Butterscotch
Halls Cherry
Halls Extra Strong Menthol
Halls Honey Lemon
Halls Ice Peppermint
Halls MENTHO-LYPTUS
Halls Melon Splash
Halls Menthol
Halls Mentholyptus
Halls Mocha Mint
Halls Naturals Honey Lemon Chamomile
Halls Plus Cherry
Halls Plus Honey
Halls Plus Strawberry
Halls Spearmint
Halls Strawberry
Halls Sugar Free Black Cherry
Halls Sugar Free Citrus Blend
Halls Sugar Free Extra Strong Menthol
Halls Sugar Free Honey Berry
Halls Sugar Free Honey Lemon
Halls Sugar Free Mountain Menthol
Halls Tropical Fruit
Hallsmelon Splash Melon Splash
Hallssugar Free Extra Sugar Free Extra Strong Menthol
Han Honey Loquat Syrup
Hanbang Cataplasma
Harmon Extra Strength Pain Relieving
Harmon Extra Strength Pain Relieving Roll-on
Headache crystals
Health Smart Medicated Foot
Herbion Naturals Honey Lemon
Herbion Naturals Honey Lemon Cough Drops
Herbion Naturals Honey-Lemon Cough Drops
Herbion Naturals Mint Cough Drops
Herbion Naturals Orange
Herbion Naturals Orange Cough Drops
Hexahydrothymol
Hielo Ardiente
Honibe
 
Hot Ice Soothing Analgesic Gel
Huitomi Slimming Sports
Humphreys Bendito Alcoholado
I06-1216
I14-7371
IDI1_000820
Ice
Ice Cold Analgesic
Ice Cold Topical Analgesic Gel
Ice External Analgesic Leader
Ice Quake
Ice Quake Muscle Rub
Icy Cool Maximum Strength
Icy Hot
Icy Hot Back
Icy Hot Medicated
Icy Hot Medicated No Mess Applicator
Icy Hot Medicated Roll Large
Icy Hot Medicated Roll Medium
Icy Hot Medicated Roll, Large
Icy Hot Medicated Roll, Medium
Icy Hot Medicated, Advanced Relief
Icy Hot Medicated, Back
Icy Hot Medicated, XL
Icy Hot Naturals
Icy Hot Power Gel
Icy Hot Vanishing Scent
Icyhot Medicated
Imada Four Seasons Safe Analgesic Balm
Jakemans Blueberry
Jakemans Cherry
Jakemans Peppermint
K2 Cold Therapy
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
Kay Medic Menthol Pain Relief
Kool Comfort
Kool Comfort Pain Relieving Roll-on
Kpp Triple Action
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
La Jiao Feng Shi Gao
Lander Polar Ice
Leader Cough Drops Cherry Flavor
Leader Cough Drops Honey Lemon
Leader Cough Drops Menthol Flavor
Leader Extra Strength Medicated Pain Relief Patch
Leader Sugar Free Cough Drops Black Cherry
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
Linkus Lozenges Cough Suppressant/Oral Anesthetic
Low Sugar Cherry Flavor Fishermans Friend Menthol Cough Suppressant
Ludens Honey Lemon Throat Drops
Ludens Honey Licorice Throat Drops
Ludens Original Menthol Throat Drops
Lurosil
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Makesense Extra Strength Muscle Rub
Maxfit Freeze Gel
Maybelline New York Baby Lips Dr Rescue Medicated Balm
Medi First Plus Cherry Cough Drops
Medi-first Cherry Cough Drops
Medic Ice
Medicated Body Powder
Medicated Pain Relief
Mediflex
Medique Medikoff Drops
Medique Sugar Free Medikoff Drops
Meditowel PAIN RELIEF
Meijer Cherry Cough Drops
Meijer Honey Lemon Cough Drops
Meijer Menthol Cough Drops
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol Fresh Cough Suppressant
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Mentholatum Pain Relief Extra Strength
Mentholatum Sports Pain Relief Cold
Menthomenthol
Menthyl alcohol
Mineral Ice Pain Relieving
Miracle Foot Repair
Miracle Foot Repair Cream
Miracle Of Aloe Rub Roll On
Miracle Pain Cream
Moisture Therapy Anti-Itch
MolPort-000-849-729
MolPort-001-793-392
Moore Medical Cherry Cough Suppressant/anesthetic Drops
Moore Medical Sugar Free Black Cherry Cough Suppressant/anesthetic Drops
Moore Medical Sugar Free Menthol Cough Suppressant/anesthetic Drops
Mr Dudleys Topical Pain Relief
Muscle
Muscle Rub Ultra Strength Pain Relieving
Myo-breathe
Myorx Low Dose Pain Relieving
Myorx Pain Relieving
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Nan San Easy Flex Pain Relieving
Natural Cherry Honey Herb Throat Drops
Natural Herb cough drop
Natural Honey Herb Cough Suppressant Throat Drops
Natural Lemon Mint Herb Throat Drops
Natural Pain Relieving Lavender Breeze Cryogel
Natures Choice Cool Hot Ice
Natures Sunshine Products Everflex Topical Analgesic Pain Relief
Neoisomenthol
Nice Assorted
Nice Cherry
Nice Citrus
Nice Cool Mint
Nice Honey Lemon
Nice Menthol
No Pain More Gain
North Cough Drop
Numotizine
Olbas Lozenges Maximun Strength
Olbas Pastilles
Original Extra Strong All Natural Fishermans Friend Menthol Cough Suppressant
Ortho-nesic
Osmoflex
Oxyrub Pain Relief
Pain Relief Balmpreferred Plus Ph Preferred Plus Pharmacy
Pain Relief Therapy Patch
Pain Reliever
Pain Relieving
Pain Relieving Analgesic
Pain Relieving Patch
Pain Relieving Patch Ultra Strength
Pain Relieving Patch Ultra Strength ULTRA STRENGTH
Panitrol XR
Paraid Extra Strength Menthol Pain Relief Sleeve Knee Large Ankles Elbows
Patch Scherer Labs
Patch Walgreens
Peppermint camphor
Perfect Purity Hotice
Perfect Purity Medicated Foot Powder
Perform
Personal Care Extra Strength Cold Hot
Personal Care Ice Cold
Plaster MandAHerbalPlaster
Po Sum On Medicated
Polar Frost Cold
Power Relief
Preferred Plus Body Powder
Premier Value Medicated Foot Powder
Q Health Pain Relief Spray
Quickflex
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Raw Heat
Raw Ice
Reactice Reactivating Ice Baume
Red Lion Relief
Relief Pain Relieving Cream
Rexall Vanishing Scent Pain Relieving
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Screamin Menthol Toast
Sella Natural
Skin So Soft Bug Guard Plusitch Relief itch relief
Smith Bros Honey Lemon Cough Drops
Smith Bros Menthol Eucalyptus Cough Drops
Smith Bros Sugar-free Black Cherry Cough Drops
Sof Skin Icy Blue
Sofskin Ice Analgesic
Sombra Cool Therapy
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Stopain Cold Pain Relieving
Stopain Cold Professional Strength Pain Relieving
Stopain Extra Strength Pain Relieving
Sub-zero COOL PAIN RELIEVING
Sugar Free Cherry Fishermans Friend Menthol Cough Suppressant
Sugar Free Cherry Herb Throat Drops
Sugar Free Lemon Mint Herb Throat Drops
Sugar Free Mountain Herb Cough Suppressant Throat Drops
Sugar Free Original Swiss Herb Cough Suppressant Throat Drops
Sugar Free Refreshing Mint Fishermans Friend Menthol Cough Suppressant
Sugar Free Swiss Cherry Herb Throat Drops
The Medicine Shoppe Extra Strength Pain Relieving
The Original Natural Herb Cough Drops
Therafreeze
Theraid
Therapeutic Relief Preferred Plus Pharmacy
Theraplus Plus
Throat Coat
Tianhe Guben Yaoshen Tie Gao
Top Care Medicated
Topcare Medicated
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
Ultra Strength Stopain Pain Relieving
Us Favorite Cold Pain Relieving
Vaporizing Colds Rub
Vicks Vapodrops Cough Relief
Vitaminerals Inc. Cryogel Natural Pain Relieving
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
Walgreens Aloe Vera Cooling
Watermelon Frost Sore Throat
Wellpatch Backache Pain Relief
Xtracare Ice Cold Topical Analgesic Gel
Youngevity Invision CM
Yun Xiang Jing
ZINC01482164
Zhong Hua Jiu Patch
Zims Arnica Max
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
33
FosaprepitantapprovedPhase 4, Phase 3148172673-20-0219090
Synonyms:
Fosaprepitant dimeglumine
 
Fosaprepitantum
L-758,298
L-758298
34
PrednisoloneapprovedPhase 4, Phase 2, Phase 3103350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
Flo-pred
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
MLS001304083
 
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
Millipred
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Omnipred
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
35
IsofluraneapprovedPhase 48026675-46-73763
Synonyms:
1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether
1-chloro-2,2,2-Trifluoroethyl difluoromethyl ether
2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane
26675-46-7
AC-154802
AC1L1GNN
AErrane (Veterinary)
Aerrane
BRN 1852087
C07518
CCRIS 3043
CHEBI:6015
CHEMBL1256
CID3763
Compound 469
D00545
D007530
DB00753
EINECS 247-897-7
Ethane
Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl
 
Forane
Forane (TN)
Forene
I14-1303
IsoFlo
Isoflurane
Isoflurane (JP15/USP/INN)
Isoflurane [Anaesthetics, volatile]
Isoflurane [USAN:BAN:INN:JAN]
Isoflurane [USAN:INN:BAN:JAN]
Isoflurane [Usan:Ban:Inn:Jan]
Isoflurano
Isoflurano [INN-Spanish]
Isofluranum
Isofluranum [INN-Latin]
Jsp005223
LS-7462
MolPort-000-153-606
NCGC00181037-01
R-E 235dal
ST51041445
Terrell
UNII-CYS9AKD70P
isoflurane
36
OndansetronapprovedPhase 4, Phase 3, Phase 226899614-02-54595
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4 (mono-hydrochloride)
99614-02-5
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
GR 38032
GR 38032X
GR-38032F
GR38032F
HMS2090H16
I06-0687
I06-1329
L000456
 
LS-172305
LS-51878
MolPort-001-944-253
NCI60_022780
Novo-ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
Ondansetron Hydrochloride
Ondansetron [USAN:INN:BAN]
Ondansetron hydrochloride dihydrate
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
SN-307
SPBio_002938
STK370548
STOCK4S-10990
Sandoz ondansetron
TL8006071
TimTec1_001750
UNII-4AF302ESOS
ZOFRAN IN PLASTIC CONTAINER
Zofran
Zofran ODT
Zofran ODT (TN)
Zofran odt
Zophren
Zudan
Zuplenz
ondansetron
ondansetron (Zofran)
37
MethylprednisoloneapprovedPhase 4, Phase 2, Phase 3103383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
A-methapred
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Depo-medrol
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Solu-medrol
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
38
Dexamethasoneapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1180650-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
39
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0252550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
40
Levonorgestrelapproved, investigationalPhase 4261797-63-7, 17489-40-613109
Synonyms:
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
(-)-Norgestrel
(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one
)-Norgestrel
121714-72-5
13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE
13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one
13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one
13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
17-Ethynyl-18-methyl-19-nortestosterone
17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one
17-alpha-Ethynyl-13-ethyl-19-nortestosterone
17alpha-Ethynyl-13-ethyl-19-nortestosterone
17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol
17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17alpha-Ethynyl-18-homo-19-nor-testosterone
17alpha-Ethynyl-18-homo-19-nortestosterone
17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one
18,19-Dinor-4-pregnen-20-yn-3-one
18-Methyl-17-alpha-ethynyl-19-nortestosterone
18-Methylnorethisterone
4222-79-1
6533-00-2
72-HOURS
797-62-6
797-63-7
AC1L211U
AC1Q6OEV
Aftera
Afterpill
BAY 86-5028
BAY86-5028
BIDD:PXR0194
BPBio1_000932
BRD-K35189033-001-03-0
BRN 2391114
BSPBio_000846
Bio-0595
C08149
C08153
CCRIS 6525
CCRIS 9033
CHEBI:44593
CHEBI:6443
CHEMBL1389
CID13109
CPD000059117
Capronor
D(−
D(-)-Norgestrel
D-(-)-Norgestrel
D-Norgestrel
D00950
D00954
DB00367
DB00506
E-Gen-C
EINECS 212-349-8
EINECS 229-433-5
Econtra Ez
FH 122-A
Fallback Solo
Follistrel
HMS1570K08
HMS2051M08
HMS2090O06
HSDB 3595
HSDB 6483
Jadelle
Jaydess
LD norgestrel [French]
LMST02030119
LO/Ovral
LS-62083
LS-62084
Ld norgestrel
Levlen
Levlen ED
Levonelle
Levonelle, D-Norgestrel, Levonova, Levonorgestrel
Levonorgestrel
Levonorgestrel (JAN/USP/INN)
Levonorgestrel Emergency Contraceptive
Levonorgestrel [USAN:INN:BAN]
Levonorgestrel implants
Levonorgestrelum
Levonorgestrelum [INN-Latin]
Levonova
Levora-21
Levora-28
Logynon ED
Lévonorgestrel
MLS000069491
MLS000759484
MLS001074069
 
Methylnorethindrone
Microgest ED
Microgyn
Microgynon 21
Microgynon 28
Microgynon 30 ED
Microgynon CD
Microlut
Microlution
Microluton
Microval
Minivlar 30
Mirena
Mirena (TN)
MolPort-002-510-453
Monofeme 28
Monovar
My Way
N2260_FLUKA
N2260_SIGMA
NCGC00159349-02
NCGC00159349-03
NORPLANT
NSC744007
Neogest
Neogynon 21
Next Choice
Next Choice One Dose
NorLevo
Nordet
Nordette 21
Nordette 28
Norgeston
Norgestrel (JP15/USP/INN)
Norgestrel [Progestins]
Norgestrel [USAN:BAN:INN:JAN]
Norgestrel [USAN:INN:BAN:JAN]
Norgestrel-(-)-D
Norgestrelum
Norgestrelum [INN-Latin]
Norlevo
Norplant (TN)
Norplant 2
Norplant II
Norplant System in Plastic Container
Norplant-2
Opcicon One-step
Ovoplex 30-150
Ovral-Lo
Ovranette
Ovrette
Ovrette (TN)
Plan B
Plan B One-step
Plan b
Postinor
Postinor-2
Prestwick0_000773
Prestwick1_000773
Prestwick2_000773
Prestwick3_000773
Prestwick_109
Preven
Rigevidon 21+7
S1727_Selleck
SAM001246694
SH 70850
SH 850
SMR000059117
SMR000653526
SOH-075
SPBio_002785
Skyla
Stediril 30
Take Action
Tetragynon
Tri-Levlen 21
Triagynon
Triciclor
Trifeme 28
Trigoa
Trinordiol 21
Trinordiol 28
Triphasil 21
Triphasil 28
Triquilar ED
Trivora
UNII-3J8Q1747Z2
UNII-5W7SIA7YZW
Wy 3707
Wy-3707
Wy-5104
ZINC03814395
alpha-Norgestrel
component of Lo/ovral
d(-)-Norgestrel
dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone
dl-Norgestrel
norgestrel
41
BicalutamideapprovedPhase 4, Phase 3, Phase 2, Phase 115890357-06-556069, 2375
Synonyms:
(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide
4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
90357-06-5
AC-4232
AC1L1DJE
Astra brand of bicalutamide
AstraZeneca brand of bicalutamide
BRN 5364666
Bicalutamide
Bicalutamide (JAN/USP/INN)
Bicalutamide [USAN:INN:BAN]
C053541
C08160
C18H14F4N2O4S
CHEMBL409
CID2375
CPD000466329
Casodex
Casodex (TN)
Casodex, Cosudex, Calutide, Kalumid, Bicalutamide
Cosudex
D00961
DB01128
FT-0080576
 
HMS2051B13
HMS2089N12
I06-0475
I06-0480
ICI 176334
ICI-176334
KS-1161
LS-119125
MLS000759437
MLS001424047
MolPort-003-845-034
MolPort-006-808-679
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
NCGC00167977-01
NCGC00167977-02
NSC722665
Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,
Raffolutil
S1190_Selleck
SAM001246612
SMR000466329
TL8005814
Zeneca brand of bicalutamide
bicalutamide
propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-)
42
TamoxifenapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 034110540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Soltamox
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
43
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1152523214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
44
Aprepitantapproved, investigationalPhase 4, Phase 3148170729-80-3151165, 6918365
Synonyms:
170729-80-3
221350-96-5
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
AC1L45SL
AC1OCFCG
Aprepitant
Aprepitant (JAN/USAN/INN)
Aprepitant [USAN]
Aprepitantum
Aprépitant
CHEBI:323967
CHEBI:499361
CHEMBL135613
CHEMBL1471
CHEMBL249465
CID11214788
CID11318675
 
CID151165
CID6918365
CID9936947
CID9936948
D02968
DB00673
Emend
Emend (TN)
HMS2090N12
I06-1151
L 754030
L-754030
LS-156477
MK 0869
MK 869
MK-0517
MK-0869
MK-869
MK-869, L-754030, Emend, Aprepitant
MolPort-006-392-367
NCGC00181785-01
ONO-7436
S1189_Selleck
UNII-1NF15YR6UY
45
PamidronateapprovedPhase 4, Phase 3, Phase 24240391-99-94674
Synonyms:
(3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID
(3-Amino-1-hydroxypropylidene)bisphosphonic acid
(3-Amino-1-hydroxypropylidene)diphosphonic acid
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
(3-amino-1-hydroxypropylidene)-1,1-biphosphonate
(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate
1-hydroxy-3-aminopropane-1,1-diphosphonic acid
3-Amino-1-hydroxypropylidene-1,1-diphosphonate
40391-99-9
57248-88-1
57248-88-1 (di-hydrochloride salt)
AC1L1IP4
AHPrBP
AKOS003599275
APD
Acide pamidronique
Acide pamidronique [INN-French]
Acido pamidronico
Acido pamidronico [INN-Spanish]
Acidum pamidronicum
Acidum pamidronicum [INN-Latin]
Amidronate
Aminomux
Aredia
BIDD:GT0538
Bisphosphonate 6
C019248
C07395
C3H11NO7P2
 
CHEMBL834
CID4674
ChemDiv1_025240
D07281
DB00282
EINECS 254-905-2
HMS2090C13
HMS658L06
HSCI1_000312
I14-2407
LS-174826
MolPort-002-131-054
NCGC00159433-02
NCGC00159433-03
Novartis brand of pamidronate disodium salt
PAMIDRONATE DISODIUM
PAMIDRONIC ACID
Pamidronate Disodium
Pamidronic acid
Pamidronic acid (INN)
Pamidronic acid [INN:BAN]
Ribodroat
Ribodroat (TN)
STOCK1N-12562
UNII-OYY3447OMC
amino-1-hydroxypropane-1,1-diphosphonate
aminohydroxypropylidene diphosphonate
aminopropanehydroxydiphosphonate
pamidronate
pamidronate calcium
pamidronate monosodium
46
Granisetronapproved, investigationalPhase 4, Phase 369109889-09-03510
Synonyms:
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
109889-09-0
AC1NR4P1
APF530
BIDD:GT0272
BRL-43694
C07023
CHEMBL519643
CID5284566
D04370
Granisetron
 
Granisetron (USAN/INN)
Granisetron HCl
Granisetron Hydrochloride
Granisetron base
Granisetron hydrochloride
Granisetronum
Granisetronum [INN-Latin]
HMS2089P14
Kytril
MolPort-005-943-366
SID90340785
Sancuso
granisetron
47
BenzocaineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 015361994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
20/20 Topical Anesthetic
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Alcohol Prep Pads
Allegenal-m
Alpha-caine Topical Anesthetic
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anbesol Jr
Anbesol Maximum Strength
Anbesol Regular Strength
Anestenka
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthetic
Anesthone
Atopalm Oral Pain Relief
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Baby Anestenka
Baby Sensigel
Baby Sensigel Night Time Formula
Baby Teething Oral Pain Reliever
Bactimicina For Sore Throat
Bencocaine Topical Anesthetic
Bensokain
Benz O Sthetic
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzodent
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
Boil Ease
Boy Butter Desensitizing Lubricant
Boy Butter Extreme Desensitizing Lubricant
Boy Butter Extreme H2O Desensitizing Lubricant
Brace Relief
Budpak Baby Teething Oral Pain Reliever
Budpak Oral Maximum Strength
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Carmex Cold Sore Treatment External Analgesic
Caswell No. 430A
Cepacol Fizzlers
Cepacol Sensations Hydra
Cepacol Sensations Sore Throat Hydra citrus splash
Cepacol Sensations Warming
Certus Sting Relief Prep Pad
Chloraseptic
Chloraseptic Warming Sore Throat
Colgate Orabase
Comfortcaine Topical Anesthetic
Cvs Fast Acting Baby Teething
Cvs Maximum Strength
Cvs Maximum Strength Boil Relief
Cvs Oral Anesthetic
Cvs Pharmacy Instant Toothache
Cvs Pharmacy Maximum Strength
Cvs Pharmacy Mouth Sore Gel
Cvs Pharmacy Nighttime Oral Pain Relief
D001566
D00552
DB01086
Dental Relief
Dentek Instant Pain Relief Maximum Strength
Dermoplast
Diet Ayds
DivK1c_000932
Dollar General Toothache Relief
Dukal Sting Relief Pad
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Finafta Baby
Finafta MultiOral
Formate, Benzocaine
Gelato Topical Anesthetic
Good Neighbor Pain Relief
Goodsense Oral Pain Relief
Gps Topical Anesthetic
Gumnumb Topical Anesthetic
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Heb Severe Toothache
Herbasoul Male Genital Desensitizer Cream
 
Hurricaine
Hurricaine Topical Anesthetic
Hurricaine Topical Anesthetic Gel
Hurricaine Topical Anesthetic Liquid
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
Insect Bite Relief
Instant Toothache Pain Relief
Intense Cvs Intense Toothache
Iodent Maximum Strength Oral Analgesic
Ismile Topical Anesthetic
Jianze Sting Relief Pads
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Kank-a Mouth Pain
Keloform
Kmart Smart Sense
Kroger Toothache Pain Relief
LS-35847
Leader Oral Analgesic
Little Colds Sore Throat Relief Melt Aways
MLS001331704
MLS002153970
Makesense Junior Pain Relief
Makesense Pain Relief
Male Desensitizer Pleasure Balm
Mandelay Male Genital Desensitizer
Mark 3
Methanesulfonate, Benzocaine
MolPort-000-871-526
Mouth Sore Medication
Mouth Sore Relief Applicator
Mouth Sore Relief Professional Strength
My Fair Baby Instant Pain Relief
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Nene Dente
Norcain
Norcaine
Norcainum
Opahl
Opahl Dye Free
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orajel For All Mouth Sores Maximum Strength
Orajel For Cold Sores
Orajel For Toothache Maximum Strength
Orajel Instant Pain Relief Maximum Strength
Orajel Instant Pain Relief Regular Strength
Orajel Instant Relief For Teething Pain
Orajel Instant Relief For Teething Pain Cooling Cucumber
Orajel Instant Relief For Teething Pain Daytime Nighttime Twin Pack
Orajel Instant Relief For Teething Pain Longer Lasting
Orajel Maximum Strength
Orajel Nighttime Instant Relief For Teething Pain Longer Lasting Extra Strength
Orajel Severe Toothache Maximum Strength Fast-Acting Formula
Oral Analgesic Maximum Strength
Oral B Instant Pain Relief
Oral Gel Maximum Strength
Oral Pain Relief Anesthetic Anesthetic
Oral Pain Reliever
Oralabs Cold Sore Treatment
Orthesin
Otocain
Outgro
Pac-dent Top Gel
Pain Relief
Pain Relief Alcohol Swabs
Parathesin
Parathesin (TN)
Parathesine
Physicians Care Sting Relief Pad
Pleasure Balm Kama Sutra
Preboost
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
Purelife Topical Anesthetic
Quality Choice Maximum Strength Oral Pain Relieving
Red Cross Oral Pain Relief
Rexall Maximum Strength
Rite Aid Baby Care
Rite Aid Liquid Anesthetic Oral Pain Relief
Rite Aid Maximum Strength
Rite Aid Oral Pain Reliever
Rite Aid Professional Strength
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Sally Hansen Ouch-relief Numbing Wipes
Sally Hansen Ouch-relief Wax Kit
Sally Hansen Ouch-relief Wax Strip Kit
Sensigel
Severe Oral Pain Reliever
Sheffield Baby Teething Gel
Sheffield Pain Relief
Shunga Male Genital Desensitizer
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Sting Relief Medicated Pad
Sting Relief Pads
Tanac
Terrasil Boil Pain Relief
Tiger Supply Inc Topical Anesthetic
Top Quality Mfg. Topical Anesthetic
Topcaine
Topcare Maximum Strength
Topical Anesthetic Banana
Topical Anesthetic Bubble Gum
Topical Anesthetic Cherry
Topical Anesthetic Mint
Topical Anesthetic Pina Colada
Topical Anesthetic Raspberry
Topical Anesthetic Strawberry
UNII-U3RSY48JW5
Ultracare Anesthetic Bubble Gum
Ultracare Anesthetic Butter Rum
Ultracare Anesthetic Creme de Menthe
Ultracare Anesthetic Pina Colada
Ultracare Anesthetic Walterberry
WLN: ZR DVO2
Walgreens Baby Teething
Walgreens Intense Toothache
Walgreens Maximum Strength
Walgreens Pain Relieving For Boils
Walgreens Severe Oral Pain Reliever
Walgreens Severe Toothache Relief
Winco Foods Maximum Strength Oral Analgesic
ZINC12358719
Zilactin-b
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
48
Capecitabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11179154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
49
Anastrozoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0252120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
50
DopamineapprovedPhase 4, Phase 3, Phase 2, Phase 0281462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8

Interventional clinical trials:

(show top 50)    (show all 5320)
idNameStatusNCT IDPhase
1Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast CancerCompletedNCT00334139Phase 4
2Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4
3Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone MetastasesCompletedNCT00434317Phase 4
4Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEXCompletedNCT00590213Phase 4
5Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDsCompletedNCT00461253Phase 4
6Randomized Trial of Follow-up Strategies in Breast CancerCompletedNCT00156039Phase 4
7Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor TherapyCompletedNCT00784888Phase 4
8Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer PatientsCompletedNCT00128778Phase 4
9Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer PatientsCompletedNCT01298193Phase 4
10Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast CancerCompletedNCT00493350Phase 4
11Pamidronate Administration in Breast Cancer Patients With Bone MetastasesCompletedNCT00128297Phase 4
12Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary TreatmentCompletedNCT01859936Phase 4
13XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast CancerCompletedNCT00127933Phase 4
14Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotCompletedNCT01553903Phase 4
15Life Quality and Mental State in Patients With Breast CancerCompletedNCT01458457Phase 4
16Wellbutrin XL, Major Depressive Disorder and Breast CancerCompletedNCT00234195Phase 4
17Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With LetrozoleCompletedNCT00237224Phase 4
18Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor ExcisionCompletedNCT00575354Phase 4
19Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer PatientsCompletedNCT01129336Phase 4
20Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00022386Phase 4
21Letrozole in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT00014638Phase 4
22Reducing Pain and Disability After Breast Cancer SurgeryCompletedNCT01089933Phase 4
23Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast CancerCompletedNCT00638599Phase 4
24A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00544986Phase 4
25Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast CancerCompletedNCT00372476Phase 4
26Arthralgia During Anastrozole Therapy for Breast CancerCompletedNCT00323479Phase 4
27A Study of Patients With HER2-Positive Metastatic Breast CancerCompletedNCT00105456Phase 4
28The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.CompletedNCT00356148Phase 4
29Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor TherapyCompletedNCT00485953Phase 4
30Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast CancerCompletedNCT00880022Phase 4
31Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast CancerCompletedNCT01199432Phase 4
32An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)CompletedNCT00726661Phase 4
33Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic AcidCompletedNCT00172029Phase 4
34Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast CancerCompletedNCT00082277Phase 4
35Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast CancerCompletedNCT00742222Phase 4
36The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast CancerCompletedNCT01907880Phase 4
37A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast CancerCompletedNCT00649090Phase 4
38A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast CancerCompletedNCT01094184Phase 4
39Low Level Laser Treatment and Breast Cancer Related LymphedemaCompletedNCT00852930Phase 4
40Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast CancerCompletedNCT00688909Phase 4
41Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal WomenCompletedNCT00237133Phase 4
42Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer PatientsCompletedNCT00882089Phase 4
43Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer RliskCompletedNCT00839696Phase 4
44Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer SurgeryCompletedNCT00768222Phase 4
45A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast CancerCompletedNCT00121836Phase 4
46Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PETCompletedNCT00904410Phase 4
47A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin TreatmentCompletedNCT01301729Phase 4
48Chlorhydrate of Ropivacaine and Breast Cancer SurgeryCompletedNCT00370240Phase 4
49Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast CancerCompletedNCT00160901Phase 4
50Promoting Breast Cancer Screening in Non-adherent WomenCompletedNCT01332032Phase 4

Search NIH Clinical Center for Breast Cancer

Inferred drug relations via UMLS65/NDF-RT43:

Show with subtypes


Cochrane evidence based reviews: Breast Neoplasms

Genetic Tests for Breast Cancer

About this section

Genetic tests related to Breast Cancer:

id Genetic test Affiliating Genes
1 Breast Cancer, Somatic22 KRAS
2 Breast Cancer, Susceptibility to24
3 Breast Cancer, Early-Onset24
4 Neoplasm of Breast24
5 Carcinoma of Male Breast24

Anatomical Context for Breast Cancer

About this section

MalaCards organs/tissues related to Breast Cancer:

33
Breast, Bone, Lymph node, Endothelial, Testes, Lung, Prostate

Animal Models for Breast Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Breast Cancer:

38 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:001076812.6AGTR1, AKT1, ATM, BARD1, BRCA1, BRCA2
2MP:000538412.4AKT1, ATM, BARD1, BRCA1, BRCA2, CASP8
3MP:000537812.4AGTR1, AKT1, ATM, BARD1, BRCA1, BRCA2
4MP:000538012.2AKT1, ATM, BARD1, BRCA1, BRCA2, CASP8
5MP:000200612.2AKT1, ATM, BARD1, BRCA1, BRCA2, CDH1
6MP:001077112.0AKT1, BRCA1, BRCA2, CASP8, CDH1, KRAS
7MP:000537611.9AGTR1, AKT1, BRCA1, BRCA2, CASP8, CDH1
8MP:000538711.9AGTR1, AKT1, ATM, BRCA1, BRCA2, CASP8
9MP:000538511.8AGTR1, AKT1, BRCA1, CASP8, CDH1, KRAS
10MP:000287311.8AKT1, BARD1, BRCA1, BRCA2, CDH1, KRAS
11MP:000538911.4AKT1, ATM, BRCA1, BRCA2, CDH1, HMMR
12MP:000537911.3AKT1, ATM, BRCA1, BRCA2, CASP8, CDH1

Publications for Breast Cancer

About this section

Articles related to Breast Cancer:

(show top 50)    (show all 25152)
idTitleAuthorsYear
1
17I^-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells. (26022099)
2015
2
Modulation of Cyclins, p53 and Mitogen-Activated Protein Kinases Signaling in Breast Cancer Cell Lines by 4-(3,4,5-Trimethoxyphenoxy)benzoic Acid. (24406729)
2014
3
Prognostic Significance of Ki-67 in Chemotherapy-naive Breast Cancer Patients with 10-year Follow-up. (24403472)
2014
4
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. (24970803)
2014
5
N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling. (25153349)
2014
6
Evaluation of the contribution of cyclooxygenase 2 genotypes to breast cancer in Taiwan. (25368279)
2014
7
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. (24390149)
2014
8
The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence. (23717438)
2013
9
Lysyl oxidase plays a pivotal role in promoting metastasis of breast cancer cells. (24422044)
2013
10
Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. (23135572)
2013
11
Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. (23291984)
2013
12
CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy. (23260003)
2013
13
DNA methylation pattern of the SLC25A43 gene in breast cancer. (22430806)
2012
14
17I^-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. (21818323)
2011
15
Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. (19855437)
2010
16
GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis. (20306294)
2010
17
Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration. (20507565)
2010
18
Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. (19763819)
2010
19
Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. (19111386)
2009
20
Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy. (19338651)
2009
21
MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. (18790736)
2008
22
Clinicopathologic and prognostic characteristics of triple-negative breast cancer. (19145094)
2008
23
Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. (17574038)
2007
24
Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression. (17804714)
2007
25
MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. (17549610)
2007
26
Tumor HGF lacks prognostic significance in Mexican breast cancer patients. (17167976)
2006
27
Skeletal health in postmenopausal survivors of early breast cancer. (15645435)
2005
28
Detailed chromosomal characterization of the breast cancer cell line MCF7 with special focus on the expression of the serine-threonine kinase 15. (15944763)
2005
29
Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. (15656883)
2005
30
No association between BRCA2 N372H and breast cancer risk. (15894703)
2005
31
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. (15987444)
2005
32
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. (15956258)
2005
33
The insulin-like growth factor system in advanced breast cancer. (14687598)
2004
34
Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells. (15268900)
2004
35
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. (14581342)
2003
36
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. (12672316)
2003
37
Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis. (12914763)
2003
38
Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor. (12396561)
2002
39
The menopause, hormone replacement therapy and breast cancer. (12650709)
2002
40
Loss of fragile histidine triad expression and metastasis in breast cancer]. (12452072)
2002
41
Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? (11469882)
2001
42
Prognostic value of cytosolic p53 protein in breast cancer. (11553865)
2001
43
Expression of a novel factor, com1, in early tumor progression of breast cancer. (10815897)
2000
44
HER2 regulatory control of angiopoietin-2 in breast cancer. (10922985)
2000
45
Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. (9568187)
1998
46
Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results. (8877013)
1996
47
GnRH analogs in benign breast disease and breast cancer chemoprevention. A challenge for the year 2000. (8005138)
1994
48
Breast cancer is associated with loss of the c-kit oncogene product. (1385336)
1992
49
Factors influencing mutation at the hprt locus in T-lymphocytes: women treated for breast cancer. (1742733)
1991
50
Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. (2575406)
1989

Variations for Breast Cancer

About this section

UniProtKB/Swiss-Prot genetic disease variations for Breast Cancer:

67 (show all 75)
id Symbol AA change Variation ID SNP ID
1AKT1p.Glu17LysVAR_055422rs121434592
2BRCA1p.Leu22SerVAR_007756
3BRCA1p.Cys61GlyVAR_007757rs28897672
4BRCA1p.Cys64GlyVAR_007758
5BRCA1p.Val271MetVAR_007761rs80357244
6BRCA1p.Phe461LeuVAR_007765rs56046357
7BRCA1p.Tyr465AspVAR_007766
8BRCA1p.Gly552ValVAR_007768
9BRCA1p.Leu892SerVAR_007775
10BRCA1p.Gly960AspVAR_007776
11BRCA1p.Thr1025IleVAR_007778
12BRCA1p.Val1047AlaVAR_007781
13BRCA1p.Pro1150SerVAR_007782rs80357272
14BRCA1p.Ala1708GluVAR_007796rs28897696
15BRCA1p.Met1775ArgVAR_007799
16BRCA1p.Glu10LysVAR_020679
17BRCA1p.Glu23LysVAR_020680
18BRCA1p.Asp749TyrVAR_020683
19BRCA1p.Ser1187IleVAR_020690
20BRCA1p.Gln1200HisVAR_020691rs56214134
21BRCA1p.Arg1204IleVAR_020692
22BRCA1p.Lys1207AsnVAR_020693
23BRCA1p.Ser1217TyrVAR_020695
24BRCA1p.Arg1699TrpVAR_020703
25BRCA1p.Met1775LysVAR_063212
26BRCA2p.Phe32LeuVAR_005085
27BRCA2p.Lys53ArgVAR_005086
28BRCA2p.Phe81LeuVAR_005088
29BRCA2p.Pro201ArgVAR_005089
30BRCA2p.Val211AlaVAR_005090
31BRCA2p.Pro222SerVAR_005091
32BRCA2p.Cys554TrpVAR_005095
33BRCA2p.Asp728AlaVAR_005097
34BRCA2p.Gly2274ValVAR_005105
35BRCA2p.His2415AsnVAR_005106
36BRCA2p.Gln2421HisVAR_005107
37BRCA2p.Met3118ThrVAR_005110
38BRCA2p.Thr3357ArgVAR_005111
39BRCA2p.Glu2089AspVAR_008783
40BRCA2p.Thr2722ArgVAR_018661
41BRCA2p.Ser1179AsnVAR_020715
42BRCA2p.Cys1580TyrVAR_020719
43BRCA2p.Thr1679IleVAR_020720
44BRCA2p.Val1804AlaVAR_020721
45BRCA2p.Glu1901LysVAR_020722
46BRCA2p.Ser2072CysVAR_020725
47BRCA2p.Tyr2094CysVAR_020726
48BRCA2p.Pro2096LeuVAR_020727
49BRCA2p.Lys2128AsnVAR_020729
50BRCA2p.Val2728IleVAR_020736rs28897749
51BRCA2p.Lys2729AsnVAR_020737rs80359065
52BRCA2p.Asn3124IleVAR_020743
53BRCA2p.Lys3196GluVAR_020744rs80359228
54BRCA2p.Gly25ArgVAR_028167
55BRCA2p.Trp31CysVAR_028168
56BRCA2p.Trp31ArgVAR_028169
57BRCA2p.Thr64IleVAR_032712
58BRCA2p.Ser326ArgVAR_032717rs28897706
59BRCA2p.Ile505ThrVAR_032718rs28897708
60BRCA2p.Ile729MetVAR_032719
61BRCA2p.Lys1690AsnVAR_032722
62BRCA2p.Asn1730TyrVAR_032723
63BRCA2p.Thr1887MetVAR_032724
64BRCA2p.Asn2135HisVAR_032728
65BRCA2p.Tyr2222CysVAR_032729
66BRCA2p.Gln2456GluVAR_032731
67BRIP1p.Pro47AlaVAR_020896rs28903098
68BRIP1p.Met299IleVAR_020900
69CHEK2p.Tyr390CysVAR_073020
70FAM175Ap.Arg361GlnVAR_071865rs201627097
71NBNp.Leu150PheVAR_025795
72PIK3CAp.Glu542LysVAR_026173
73PIK3CAp.Glu545LysVAR_026178
74PIK3CAp.His1047ArgVAR_026192
75RAD51p.Arg150GlnVAR_010899rs121917739

Clinvar genetic disease variations for Breast Cancer:

5 (show all 1,687)
id Gene Variation Type Significance SNP ID Assembly Location
1PALB2NM_024675.3(PALB2): c.3549C> G (p.Tyr1183Ter)single nucleotide variantPathogenic, risk factorrs118203998GRCh37Chr 16, 23614792: 23614792
2PALB2NM_024675.3(PALB2): c.2962C> T (p.Gln988Ter)single nucleotide variantPathogenic, risk factorrs118203999GRCh37Chr 16, 23634324: 23634324
3BRCA1NM_007294.3(BRCA1): c.1812delA (p.Ala605Hisfs)deletionPathogenicrs80357927GRCh38Chr 17, 43093719: 43093719
4BRCA1NM_007294.3(BRCA1): c.2995_2996delCTinsTA (p.Leu999Ter)indelPathogenicrs273899692GRCh38Chr 17, 43092535: 43092536
5BRCA2NM_000059.3(BRCA2): c.891_899delAACAGTTGTinsGATACTTCAG (p.Thr298Ilefs)indelPathogenicrs276174914GRCh38Chr 13, 32332369: 32332377
6BRCA2NM_000059.3(BRCA2): c.1190_1191insTTAG (p.Gln397Hisfs)insertionPathogenicrs80359266GRCh37Chr 13, 32906805: 32906806
7BRCA2NM_000059.3(BRCA2): c.5222_5225delGTAA (p.Ser1741Thrfs)deletionPathogenicrs80359498GRCh37Chr 13, 32913714: 32913717
8BRCA2NM_000059.3(BRCA2): c.8188G> C (p.Ala2730Pro)single nucleotide variantLikely pathogenicrs80359066GRCh37Chr 13, 32937527: 32937527
9PALB2NM_024675.3(PALB2): c.1027C> T (p.Gln343Ter)single nucleotide variantPathogenic, risk factorrs180177097GRCh38Chr 16, 23635519: 23635519
10PALB2NM_024675.3(PALB2): c.1050_1051delAAinsTCT (p.Gln350Hisfs)indelPathogenicrs180177098GRCh38Chr 16, 23635495: 23635496
11PALB2NM_024675.3(PALB2): c.1056_1057delGA (p.Lys353Ilefs)deletionPathogenicrs180177099GRCh38Chr 16, 23635489: 23635490
12PALB2NM_024675.3(PALB2): c.1314delA (p.Phe440Leufs)deletionPathogenicrs515726065GRCh38Chr 16, 23635232: 23635232
13PALB2NM_024675.3(PALB2): c.1317delG (p.Phe440Leufs)deletionPathogenicrs515726067GRCh38Chr 16, 23635229: 23635229
14PALB2NM_024675.3(PALB2): c.1479delC (p.Thr494Leufs)deletionPathogenicrs515726071GRCh38Chr 16, 23635067: 23635067
15PALB2NM_024675.3(PALB2): c.1592delT (p.Leu531Cysfs)deletionPathogenic, risk factorrs180177102GRCh38Chr 16, 23634954: 23634954
16PALB2NM_024675.3(PALB2): c.1633G> T (p.Glu545Ter)single nucleotide variantPathogenicrs180177103GRCh38Chr 16, 23634913: 23634913
17PALB2NM_024675.3(PALB2): c.172_175delTTGT (p.Gln60Argfs)deletionPathogenic, risk factorrs180177143GRCh38Chr 16, 23637886: 23637889
18PALB2NM_024675.3(PALB2): c.1947dupA (p.Glu650Argfs)duplicationPathogenicrs515726075GRCh38Chr 16, 23630207: 23630207
19PALB2NM_024675.3(PALB2): c.196C> T (p.Gln66Ter)single nucleotide variantPathogenicrs180177083GRCh38Chr 16, 23637865: 23637865
20PALB2NM_024675.3(PALB2): c.2145_2146delTA (p.Asp715Glufs)deletionPathogenicrs515726081GRCh38Chr 16, 23630008: 23630009
21PALB2NM_024675.3(PALB2): c.229delT (p.Cys77Valfs)deletionPathogenicrs180177084GRCh38Chr 16, 23636317: 23636317
22PALB2NM_024675.3(PALB2): c.2323C> T (p.Gln775Ter)single nucleotide variantPathogenic, risk factorrs180177111GRCh38Chr 16, 23629831: 23629831
23PALB2NM_024675.3(PALB2): c.2386G> T (p.Gly796Ter)single nucleotide variantPathogenicrs180177112GRCh38Chr 16, 23629768: 23629768
24PALB2NM_024675.3(PALB2): c.2390delA (p.Gln797Hisfs)deletionPathogenicrs515726086GRCh38Chr 16, 23629764: 23629764
25PALB2PALB2: c.2515-1G> Tsingle nucleotide variantLikely pathogenic, Pathogenic, risk factorrs587776417GRCh38Chr 16, 23629276: 23629276
26PALB2NM_024675.3(PALB2): c.2559C> T (p.Gly853=)single nucleotide variantLikely pathogenicrs180177115GRCh38Chr 16, 23629231: 23629231
27PALB2NM_024675.3(PALB2): c.2587-?_3201+?del (p.Asn863_Met1067del)deletionPathogenic
28PALB2NM_024675.3(PALB2): c.2686dupT (p.Ser896Phefs)duplicationPathogenicrs515726091GRCh38Chr 16, 23626298: 23626298
29PALB2NM_024675.3(PALB2): c.2718G> A (p.Trp906Ter)single nucleotide variantPathogenicrs180177122GRCh38Chr 16, 23626266: 23626266
30PALB2NM_024675.3(PALB2): c.2761C> T (p.Gln921Ter)single nucleotide variantPathogenicrs180177124GRCh38Chr 16, 23624082: 23624082
31PALB2NM_024675.3(PALB2): c.2835-1G> Csingle nucleotide variantLikely pathogenicrs515726099GRCh38Chr 16, 23623131: 23623131
32PALB2NM_024675.3(PALB2): c.2920_2921delAA (p.Lys974Glufs)deletionPathogenicrs180177126GRCh38Chr 16, 23623044: 23623045
33PALB2NM_024675.3(PALB2): c.2982dupT (p.Ala995Cysfs)duplicationPathogenicrs180177127GRCh38Chr 16, 23622983: 23622983
34PALB2NM_024675.3(PALB2): c.3026delC (p.Pro1009Leufs)deletionPathogenicrs180177131GRCh38Chr 16, 23621449: 23621449
35PALB2NM_024675.3(PALB2): c.3048delT (p.Phe1016Leufs)deletionPathogenicrs515726104GRCh38Chr 16, 23621427: 23621427
36PALB2NM_024675.3(PALB2): c.3113G> A (p.Trp1038Ter)single nucleotide variantPathogenic, risk factorrs180177132GRCh38Chr 16, 23621362: 23621362
37PALB2NM_024675.3(PALB2): c.3116delA (p.Asn1039Ilefs)deletionPathogenic, risk factorrs180177133GRCh38Chr 16, 23614089: 23614089
38PALB2NM_024675.3(PALB2): c.3202-1G> Csingle nucleotide variantLikely pathogenic, Pathogenicrs515726111GRCh38Chr 16, 23608013: 23608013
39PALB2PALB2: c.3202-?_*297del (p.Gly1068_Ser1186delins45)deletionPathogenicGRCh38Chr 16, 23603162: 23608012
40PALB2NM_024675.3(PALB2): c.3256C> T (p.Arg1086Ter)single nucleotide variantPathogenic, risk factorrs587776527GRCh38Chr 16, 23607958: 23607958
41PALB2NM_024675.3(PALB2): c.3323delA (p.Tyr1108Serfs)deletionLikely pathogenic, Pathogenicrs180177135GRCh38Chr 16, 23607891: 23607891
42PALB2NM_024675.3(PALB2): c.3362delG (p.Gly1121Valfs)deletionPathogenicrs515726117GRCh38Chr 16, 23603658: 23603658
43PALB2NM_024675.3(PALB2): c.3497delG (p.Gly1166Valfs)deletionPathogenicrs180177138GRCh37Chr 16, 23614844: 23614844
44PALB2NM_024675.3(PALB2): c.48+1G> Csingle nucleotide variantLikely pathogenicrs515726118GRCh38Chr 16, 23641109: 23641109
45PALB2NM_024675.3(PALB2): c.503C> A (p.Ser168Ter)single nucleotide variantPathogenicrs515726122GRCh38Chr 16, 23636043: 23636043
46PALB2NM_024675.3(PALB2): c.508_509delAG (p.Arg170Ilefs)deletionPathogenicrs515726123GRCh38Chr 16, 23636037: 23636038
47PALB2NM_024675.3(PALB2): c.509_510delGA (p.Arg170Ilefs)deletionPathogenicrs515726124GRCh38Chr 16, 23636036: 23636037
48PALB2NM_024675.3(PALB2): c.697delG (p.Val233Leufs)deletionPathogenicrs180177090GRCh38Chr 16, 23635849: 23635849
49PALB2NM_024675.3(PALB2): c.72delG (p.Arg26Glyfs)deletionPathogenicrs180177142GRCh38Chr 16, 23638106: 23638106
50PALB2NM_024675.3(PALB2): c.751C> T (p.Gln251Ter)single nucleotide variantPathogenicrs180177091GRCh38Chr 16, 23635795: 23635795
51PALB2NM_024675.3(PALB2): c.757_758delCT (p.Leu253Ilefs)deletionPathogenicrs180177092GRCh38Chr 16, 23635788: 23635789
52PALB2NM_024675.3(PALB2): c.758dupT (p.Ser254Ilefs)duplicationPathogenicrs515726126GRCh38Chr 16, 23635788: 23635788
53CHEK2NM_007194.3(CHEK2): c.444+1G> Tsingle nucleotide variantLikely pathogenicrs121908698GRCh37Chr 22, 29121230: 29121230
54BARD1NM_000465.3(BARD1): c.1935_1954dup20 (p.Glu652Valfs)duplicationPathogenicrs587780024GRCh37Chr 2, 215595182: 215595201
55CHEK2NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs)deletionPathogenicrs555607708GRCh37Chr 22, 29091857: 29091857
56CHEK2NM_007194.3(CHEK2): c.1111C> T (p.His371Tyr)single nucleotide variantLikely pathogenicrs531398630GRCh37Chr 22, 29091846: 29091846
57CHEK2NM_007194.3(CHEK2): c.1263delT (p.Ser422Valfs)deletionPathogenicrs587780174GRCh37Chr 22, 29091227: 29091227
58CHEK2NM_007194.3(CHEK2): c.1427C> T (p.Thr476Met)single nucleotide variantLikely pathogenic, Pathogenicrs142763740GRCh37Chr 22, 29090054: 29090054
59CHEK2NM_007194.3(CHEK2): c.190G> A (p.Glu64Lys)single nucleotide variantLikely pathogenicrs141568342GRCh37Chr 22, 29130520: 29130520
60CHEK2NM_007194.3(CHEK2): c.444+1G> Asingle nucleotide variantPathogenicrs121908698GRCh37Chr 22, 29121230: 29121230
61PALB2NM_024675.3(PALB2): c.1240C> T (p.Arg414Ter)single nucleotide variantPathogenicrs180177100GRCh38Chr 16, 23635306: 23635306
62PALB2NM_024675.3(PALB2): c.3456dupA (p.Pro1153Thrfs)duplicationLikely pathogenic, Pathogenicrs587776426GRCh38Chr 16, 23603564: 23603564
63PALB2NM_024675.3(PALB2): c.3549C> A (p.Tyr1183Ter)single nucleotide variantPathogenicrs118203998GRCh38Chr 16, 23603471: 23603471
64RAD51NM_002875.4(RAD51): c.449G> A (p.Arg150Gln)single nucleotide variantPathogenicrs121917739GRCh37Chr 15, 41011016: 41011016
65PALB2NM_024675.3(PALB2): c.2167_2168delAT (p.Met723Valfs)deletionPathogenicrs587776416GRCh38Chr 16, 23629986: 23629987
66BRIP1NM_032043.2(BRIP1): c.627+1G> Asingle nucleotide variantPathogenicrs587780833GRCh37Chr 17, 59924461: 59924461
67PIK3CANM_006218.2(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
68PIK3CANM_006218.2(PIK3CA): c.3140A> T (p.His1047Leu)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
69PIK3CANM_006218.2(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
70AKT1NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)single nucleotide variantPathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
71BRCA1NM_007294.3(BRCA1): c.5205delA (p.Val1736Serfs)deletionPathogenicrs587781258GRCh37Chr 17, 41209141: 41209141
72MT-CYBm.14766C> Tsingle nucleotide variantLikely pathogenicrs527236041GRCh37Chr MT, 14766: 14766
73MT-CYBm.14783T> Csingle nucleotide variantLikely pathogenicrs527236042GRCh37Chr MT, 14783: 14783
74MT-CYBm.15043G> Asingle nucleotide variantLikely pathogenicrs527236043GRCh37Chr MT, 15043: 15043
75MT-CYBm.15287T> Csingle nucleotide variantLikely pathogenicrs527236044GRCh37Chr MT, 15287: 15287
76MT-CYBm.15301G> Asingle nucleotide variantLikely pathogenicrs527236045GRCh37Chr MT, 15301: 15301
77MT-CYBm.15326A> Gsingle nucleotide variantLikely pathogenicrs2853508GRCh37Chr MT, 15326: 15326
78BRIP1NM_032043.2(BRIP1): c.133G> T (p.Glu45Ter)single nucleotide variantPathogenicrs587781292GRCh37Chr 17, 59937229: 59937229
79PALB2NM_024675.3(PALB2): c.1546delA (p.Arg516Glufs)deletionPathogenicrs587781560GRCh37Chr 16, 23646321: 23646321
80CHEK2NM_007194.3(CHEK2): c.151C> T (p.Gln51Ter)single nucleotide variantPathogenicrs587781592GRCh37Chr 22, 29130559: 29130559
81BRCA2NM_000059.3(BRCA2): c.1909+1G> Asingle nucleotide variantLikely pathogenic, Pathogenicrs587781629GRCh37Chr 13, 32907525: 32907525
82CHEK2NM_007194.3(CHEK2): c.483_485delAGA (p.Glu161del)deletionLikely pathogenicrs587782008GRCh37Chr 22, 29121072: 29121074
83CHEK2NM_007194.3(CHEK2): c.279G> A (p.Trp93Ter)single nucleotide variantPathogenicrs587782070GRCh38Chr 22, 28734443: 28734443
84CHEK2NM_007194.3(CHEK2): c.499G> A (p.Gly167Arg)single nucleotide variantLikely pathogenicrs72552322GRCh38Chr 22, 28725070: 28725070
85PALB2NM_024675.3(PALB2): c.2931dupA (p.Val978Serfs)duplicationPathogenicrs587782570GRCh38Chr 16, 23623034: 23623034
86BARD1NM_000465.3(BARD1): c.1212C> G (p.Tyr404Ter)single nucleotide variantPathogenicrs587782681GRCh37Chr 2, 215645386: 215645386
87MT-CYBNC_012920.1: m.14800C> Tsingle nucleotide variantLikely pathogenicrs527236164GRCh37Chr MT, 14800: 14800
88MT-CYBNC_012920.1: m.14891C> Gsingle nucleotide variantLikely pathogenicrs386419981GRCh37Chr MT, 14891: 14891
89MT-CYBNC_012920.1: m.14950C> Tsingle nucleotide variantLikely pathogenicrs527236166GRCh37Chr MT, 14950: 14950
90MT-CYBNC_012920.1: m.14968T> Csingle nucleotide variantLikely pathogenicrs527236167GRCh37Chr MT, 14968: 14968
91MT-CYBNC_012920.1: m.14974C> Gsingle nucleotide variantLikely pathogenicrs527236168GRCh37Chr MT, 14974: 14974
92MT-CYBNC_012920.1: m.15001T> Csingle nucleotide variantLikely pathogenicrs527236169GRCh37Chr MT, 15001: 15001
93MT-CYBNC_012920.1: m.15049C> Tsingle nucleotide variantLikely pathogenicrs527236170GRCh37Chr MT, 15049: 15049
94MT-CYBNC_012920.1: m.15214T> Csingle nucleotide variantLikely pathogenicrs527236173GRCh37Chr MT, 15214: 15214
95MT-CYBNC_012920.1: m.15226A> Gsingle nucleotide variantLikely pathogenicrs527236174GRCh37Chr MT, 15226: 15226
96MT-CYBNC_012920.1: m.15289T> Csingle nucleotide variantLikely pathogenicrs527236175GRCh37Chr MT, 15289: 15289
97MT-CYBNC_012920.1: m.15323G> Asingle nucleotide variantLikely pathogenicrs527236177GRCh37Chr MT, 15323: 15323
98MT-CYBNC_012920.1: m.15346G> Asingle nucleotide variantLikely pathogenicrs527236180GRCh37Chr MT, 15346: 15346
99MT-CYBNC_012920.1: m.15349C> Asingle nucleotide variantLikely pathogenicrs527236201GRCh37Chr MT, 15349: 15349
100MT-CYBNC_012920.1: m.15349C> Tsingle nucleotide variantLikely pathogenicrs527236201GRCh37Chr MT, 15349: 15349
101MT-CYBNC_012920.1: m.15355G> Asingle nucleotide variantLikely pathogenicrs527236181GRCh37Chr MT, 15355: 15355
102MT-CYBNC_012920.1: m.15385C> Tsingle nucleotide variantLikely pathogenicrs527236183GRCh37Chr MT, 15385: 15385
103MT-CYBNC_012920.1: m.15458T> Csingle nucleotide variantLikely pathogenicrs527236185GRCh37Chr MT, 15458: 15458
104MT-CYBNC_012920.1: m.15470T> Csingle nucleotide variantLikely pathogenicrs527236187GRCh37Chr MT, 15470: 15470
105MT-CYBNC_012920.1: m.15553G> Asingle nucleotide variantLikely pathogenicrs527236189GRCh37Chr MT, 15553: 15553
106MT-CYBNC_012920.1: m.15637C> Tsingle nucleotide variantLikely pathogenicrs527236190GRCh37Chr MT, 15637: 15637
107MT-CYBNC_012920.1: m.15649A> Gsingle nucleotide variantLikely pathogenicrs527236191GRCh37Chr MT, 15649: 15649
108MT-CYBNC_012920.1: m.15682A> Gsingle nucleotide variantLikely pathogenicrs527236192GRCh37Chr MT, 15682: 15682
109MT-CYBNC_012920.1: m.15758A> Gsingle nucleotide variantLikely pathogenicrs527236193GRCh37Chr MT, 15758: 15758
110MT-CYBNC_012920.1: m.15784T> Csingle nucleotide variantLikely pathogenicrs527236194GRCh37Chr MT, 15784: 15784
111MT-TTNC_012920.1: m.15927G> Asingle nucleotide variantLikely pathogenicrs193303002GRCh38Chr MT, 15927: 15927
112MT-TENC_012920.1: m.14732A> Gsingle nucleotide variantLikely pathogenicrs527236202GRCh37Chr MT, 14732: 14732
113MT-CYBNC_012920.1: m.14905G> Asingle nucleotide variantLikely pathogenicrs527236203GRCh37Chr MT, 14905: 14905
114MT-CYBNC_012920.1: m.14935T> Csingle nucleotide variantLikely pathogenicrs527236204GRCh37Chr MT, 14935: 14935
115PALB2NM_024675.3(PALB2): c.3426dupA (p.Leu1143Thrfs)duplicationPathogenicrs587776425GRCh38Chr 16, 23603594: 23603594
116BRCA2NM_000059.3(BRCA2): c.8490G> A (p.Trp2830Ter)single nucleotide variantPathogenicrs587776351GRCh37Chr 13, 32945095: 32945095
117BRCA2NM_000059.3(BRCA2): c.787dupA (p.Ser263Lysfs)duplicationPathogenicrs690016538GRCh38Chr 13, 32331024: 32331024
118BRCA2NM_000059.3(BRCA2): c.3280A> T (p.Lys1094Ter)single nucleotide variantPathogenicrs690016539GRCh38Chr 13, 32337635: 32337635
119BRCA2NM_000059.3(BRCA2): c.3291dupT (p.Asn1098Terfs)duplicationPathogenicrs690016540GRCh38Chr 13, 32337646: 32337646
120BRCA2NM_000059.3(BRCA2): c.3292delA (p.Asn1098Ilefs)deletionPathogenicrs690016541GRCh38Chr 13, 32337647: 32337647
121BRCA2NM_000059.3(BRCA2): c.3641delT (p.Val1214Glyfs)deletionPathogenicrs690016542GRCh38Chr 13, 32337996: 32337996
122FHNM_000143.3(FH): c.1067T> A (p.Leu356Ter)single nucleotide variantLikely pathogenic, Pathogenicrs727503927GRCh38Chr 1, 241504083: 241504083
123BRCA1NM_007294.3(BRCA1): c.190T> G (p.Cys64Gly)single nucleotide variantPathogenicrs80357064GRCh37Chr 17, 41258495: 41258495
124BRCA1NM_007294.3(BRCA1): c.181T> G (p.Cys61Gly)single nucleotide variantPathogenicrs28897672GRCh37Chr 17, 41258504: 41258504
125BRCA1NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs)deletionPathogenic, risk factorrs386833395GRCh37Chr 17, 41276047: 41276048
126BRCA1NM_007294.3(BRCA1): c.1175_1214del40 (p.Leu392Glnfs)deletionLikely pathogenic, Pathogenicrs80359874GRCh37Chr 17, 41246334: 41246373
127BRCA1NM_007294.3(BRCA1): c.2296_2297delAG (p.Ser766Terfs)deletionPathogenicrs80357780GRCh37Chr 17, 41245251: 41245252
128BRCA1NM_007294.3(BRCA1): c.2681_2682delAA (p.Lys894Thrfs)deletionPathogenicrs80357971GRCh37Chr 17, 41244866: 41244867
129BRCA1NM_007294.3(BRCA1): c.3005delA (p.Asn1002Thrfs)deletionPathogenicrs80357601GRCh38Chr 17, 43092526: 43092526
130BRCA1NM_007294.3(BRCA1): c.3607C> T (p.Arg1203Ter)single nucleotide variantPathogenicrs62625308GRCh37Chr 17, 41243941: 41243941
131BRCA1NM_007294.3(BRCA1): c.3748G> T (p.Glu1250Ter)single nucleotide variantPathogenicrs28897686GRCh37Chr 17, 41243800: 41243800
132BRCA1NM_007294.3(BRCA1): c.3756_3759delGTCT (p.Ser1253Argfs)deletionLikely pathogenic, Pathogenicrs80357868GRCh37Chr 17, 41243789: 41243792
133BRCA1NM_007294.3(BRCA1): c.4065_4068delTCAA (p.Asn1355Lysfs)deletionLikely pathogenic, Pathogenicrs80357508GRCh37Chr 17, 41243480: 41243483
134BRCA1NM_007294.3(BRCA1): c.4327C> T (p.Arg1443Ter)single nucleotide variantPathogenicrs41293455GRCh37Chr 17, 41234451: 41234451
135BRCA1NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs)duplicationPathogenic, risk factorrs80357906GRCh37Chr 17, 41209083: 41209083
136BRCA1NM_007294.3(BRCA1): c.2389G> T (p.Glu797Ter)single nucleotide variantPathogenicrs62625306GRCh37Chr 17, 41245159: 41245159
137BRCA1NM_007294.3(BRCA1): c.843_846delCTCA (p.Ser282Tyrfs)deletionPathogenicrs80357919GRCh37Chr 17, 41246702: 41246705
138BRCA1NM_007294.3(BRCA1): c.3481_3491delGAAGATACTAG (p.Glu1161Phefs)deletionPathogenicrs80357877GRCh37Chr 17, 41244057: 41244067
139BRCA1NM_007294.3(BRCA1): c.1556delA (p.Lys519Argfs)deletionPathogenicrs80357662GRCh37Chr 17, 41245992: 41245992
140BRCA1NM_007294.3(BRCA1): c.211A> G (p.Arg71Gly)single nucleotide variantLikely pathogenic, Pathogenicrs80357382GRCh37Chr 17, 41258474: 41258474
141BRCA1NM_007294.3(BRCA1): c.5324T> G (p.Met1775Arg)single nucleotide variantPathogenicrs41293463GRCh37Chr 17, 41203088: 41203088
142BRCA1NM_007294.3(BRCA1): c.5324T> A (p.Met1775Lys)single nucleotide variantLikely pathogenic, Pathogenicrs41293463GRCh37Chr 17, 41203088: 41203088
143NM_000051.3(ATM): c.8264_8268delATAAG (p.Tyr2755Cysfs)deletionPathogenicrs730881294GRCh38Chr 11, 108335957: 108335961
144BRCA1NM_007294.3(BRCA1): c.2938delA (p.Ile980Tyrfs)deletionPathogenicrs730881439GRCh38Chr 17, 43092593: 43092593
145BRCA1NM_007294.3(BRCA1): c.3767_3768delCA (p.Thr1256Argfs)deletionPathogenicrs730881440GRCh38Chr 17, 43091763: 43091764
146BRCA1NM_007294.3(BRCA1): c.5474_5481delGGCAGATG (p.Gly1825Valfs)deletionPathogenicrs730881441GRCh38Chr 17, 43045789: 43045796
147BRCA1NM_007294.3(BRCA1): c.45delT (p.Asn16Metfs)deletionPathogenicrs730881457GRCh38Chr 17, 43124052: 43124052
148BRCA1NM_007294.3(BRCA1): c.1340_1341delTT (p.Val447Alafs)deletionPathogenicrs730881458GRCh38Chr 17, 43094190: 43094191
149BRCA1NM_007294.3: c.1363insTinsertionPathogenic
150BRCA1NM_007294.3(BRCA1): c.1860delT (p.His621Metfs)deletionPathogenicrs730881459GRCh38Chr 17, 43093671: 43093671
151BRCA1NM_007294.3: c.2726insAinsertionPathogenic
152BRCA1NM_007294.3(BRCA1): c.2945delC (p.Pro982Hisfs)deletionPathogenicrs730881461GRCh38Chr 17, 43092586: 43092586
153BRCA1NM_007294.3: c.3108insTinsertionPathogenic
154BRCA1NM_007294.3(BRCA1): c.3129_3138delTATTAATGAA (p.Asn1043Lysfs)deletionPathogenicrs730881462GRCh38Chr 17, 43092393: 43092402
155BRCA1NM_007294.3: c.3627insAinsertionPathogenic
156BRCA1NM_007294.3: c.3648insAinsertionPathogenic
157BRCA1NM_007294.3: c.3764insAinsertionPathogenic
158BRCA1NM_007294.3: c.3908insTinsertionPathogenic
159BRCA1NM_007294.3: c.4997insAinsertionPathogenic
160BRCA1NM_007294.3: c.5359_5360delTGTGGinsAGTGAinsertionPathogenic
161BRCA1NM_007294.3(BRCA1): c.869T> G (p.Leu290Ter)single nucleotide variantPathogenicrs730881468GRCh38Chr 17, 43094662: 43094662
162BRCA1NM_007294.3(BRCA1): c.4097-2A> Csingle nucleotide variantPathogenicrs80358019GRCh38Chr 17, 43091034: 43091034
163BRCA1NM_007294.3(BRCA1): c.4987-1G> Asingle nucleotide variantLikely pathogenic, Pathogenicrs730881495GRCh38Chr 17, 43067696: 43067696
164BRCA1NM_007294.3(BRCA1): c.5332+2T> Gsingle nucleotide variantPathogenicrs80358182GRCh38Chr 17, 43051061: 43051061
165BRCA2NM_000059.3(BRCA2): c.3172A> T (p.Lys1058Ter)single nucleotide variantPathogenicrs730881521GRCh38Chr 13, 32337527: 32337527
166BRCA2NM_000059.3(BRCA2): c.6685G> T (p.Glu2229Ter)single nucleotide variantPathogenicrs730881548GRCh37Chr 13, 32915177: 32915177
167BRCA2NM_000059.3(BRCA2): c.8978C> G (p.Ser2993Ter)single nucleotide variantPathogenicrs397508025GRCh38Chr 13, 32379774: 32379774
168BRCA2NM_000059.3(BRCA2): c.9648+1G> Csingle nucleotide variantPathogenicrs730881573GRCh38Chr 13, 32397045: 32397045
169BRCA2NM_000059.3(BRCA2): c.8174G> A (p.Trp2725Ter)single nucleotide variantPathogenicrs730881581GRCh38Chr 13, 32363376: 32363376
170BRCA2NM_000059.3(BRCA2): c.670_673dupGATA (p.Thr225Argfs)duplicationPathogenicrs730881601GRCh37Chr 13, 32903618: 32903621
171BRCA2NM_000059.3(BRCA2): c.2380dupA (p.Met794Asnfs)duplicationPathogenicrs730881602GRCh37Chr 13, 32910872: 32910872
172BRCA2NM_000059.3(BRCA2): c.3010delA (p.Ser1004Valfs)deletionPathogenicrs730881604GRCh38Chr 13, 32337365: 32337365
173BRCA2NM_000059.3(BRCA2): c.4112dupA (p.Phe1372Valfs)duplicationPathogenicrs730881606GRCh38Chr 13, 32338467: 32338467
174BRCA2NM_000059.3(BRCA2): c.4168_4169delTT (p.Leu1390Glyfs)deletionPathogenicrs730881607GRCh38Chr 13, 32338523: 32338524
175BRCA2NM_000059.3(BRCA2): c.4277delC (p.Thr1426Asnfs)deletionPathogenicrs730881608GRCh38Chr 13, 32338632: 32338632
176BRCA2NM_000059.3(BRCA2): c.4824_4825delGA (p.Glu1608Aspfs)deletionPathogenicrs730881610GRCh37Chr 13, 32913316: 32913317
177BRCA2NM_000059.3(BRCA2): c.6267_6270dupGCAT (p.Ser2091Alafs)duplicationPathogenicrs730881611GRCh37Chr 13, 32914759: 32914762
178BRCA2NM_000059.3(BRCA2): c.7380_7381insG (p.Asn2461Glufs)insertionPathogenicrs730881612GRCh38Chr 13, 32355233: 32355234
179BRCA2NM_000059.3(BRCA2): c.7588delC (p.Gln2530Lysfs)deletionPathogenicrs730881613GRCh38Chr 13, 32356580: 32356580
180BRCA2NM_000059.3(BRCA2): c.7979_7991delATGATACGGAAAT (p.Tyr2660Leufs)deletionPathogenicrs730881614GRCh38Chr 13, 32363181: 32363193
181BRCA2NM_000059.3(BRCA2): c.8174_8185delGGTATGCTGTTAinsTT (p.Trp2725Phefs)indelPathogenicrs730881615GRCh38Chr 13, 32363376: 32363387
182BRCA2NM_000059.3(BRCA2): c.8953+1delGdeletionPathogenicrs730881617GRCh38Chr 13, 32379516: 32379516
183BRCA2NM_000059.3(BRCA2): c.9728delC (p.Pro3243Leufs)deletionPathogenicrs730881618GRCh38Chr 13, 32398241: 32398241
184BRCA2NM_000059.3(BRCA2): c.9891_9894dupATTT (p.Gln3299Ilefs)duplicationPathogenicrs730881619GRCh38Chr 13, 32398404: 32398407
185BRCA2NM_000059.3(BRCA2): c.3820_3823delAAGA (p.Lys1274Terfs)deletionPathogenicrs730881620GRCh38Chr 13, 32338175: 32338178
186BRCA2NM_000059.3: c.3847_3848delTGdeletionPathogenic
187BRIP1NM_032043.2(BRIP1): c.2255_2256delAA (p.Lys752Argfs)deletionPathogenicrs730881649GRCh38Chr 17, 61744433: 61744434
188BRIP1NM_032043.2(BRIP1): c.890delA (p.Lys297Serfs)deletionPathogenicrs786202610GRCh37Chr 17, 59885856: 59885856
189BRIP1NM_032043.2(BRIP1): c.484C> T (p.Arg162Ter)single nucleotide variantPathogenicrs747604569GRCh37Chr 17, 59926513: 59926513
190PALB2NM_024675.3(PALB2): c.49-2A> Tsingle nucleotide variantLikely pathogenicrs786203245GRCh37Chr 16, 23649452: 23649452
191CHEK2NM_007194.3(CHEK2): c.277delT (p.Trp93Glyfs)deletionPathogenicrs786203458GRCh37Chr 22, 29130433: 29130433
192BRIP1NM_032043.2(BRIP1): c.290_293delACAA (p.Asn97Metfs)deletionPathogenicrs763009188GRCh37Chr 17, 59934505: 59934508
193PALB2NM_024675.3(PALB2): c.3114-?_3350+?deldeletionLikely pathogenic
194PALB2NM_024675.3(PALB2): c.2835-1G> Asingle nucleotide variantLikely pathogenicrs515726099GRCh37Chr 16, 23634452: 23634452
195PALB2NM_024675.3(PALB2): c.2920_2923delAAGA (p.Lys974Glyfs)deletionPathogenicrs786204122GRCh37Chr 16, 23634363: 23634366
196PALB2NM_024675.3(PALB2): c.1966_1967insAGAGGAAGCTGTATTTTTC (p.Pro656Glnfs)insertionPathogenicrs786204129GRCh38Chr 16, 23630187: 23630188
197PALB2NM_024675.3(PALB2): c.2597delG (p.Gly866Valfs)deletionPathogenicrs786204156GRCh37Chr 16, 23637708: 23637708
198BRIP1NM_032043.2(BRIP1): c.919-?_1140+?deldeletionLikely pathogenic
199PALB2NM_024675.3(PALB2): c.2587-?_*(1_?)deldeletionPathogenicGRCh38Chr 16, 23603458: 23626397
200PALB2NM_024675.3(PALB2): c.3351-?_*(1_?)deldeletionPathogenicGRCh38Chr 16, 23603458: 23603669
201BRIP1NM_032043.2(BRIP1): c.2447G> A (p.Trp816Ter)single nucleotide variantPathogenicrs786204250GRCh37Chr 17, 59793357: 59793357
202APCNM_000038.5(APC): c.170A> T (p.Asp57Val)single nucleotide variantLikely pathogenicrs794729227GRCh37Chr 5, 112102057: 112102057
203ESR1NM_000125.3(ESR1): c.908A> G (p.Lys303Arg)single nucleotide variantrisk factorrs796065354GRCh38Chr 6, 151944320: 151944320
204ATMNM_000051.3(ATM): c.4111delG (p.Asp1371Ilefs)deletionLikely pathogenicrs797045114GRCh37Chr 11, 108159705: 108159705
205BLMNM_001287246.1(BLM): c.3014_3015insTATCA (p.Met1006Ilefs)insertionLikely pathogenicrs797045115GRCh38Chr 15, 90790839: 90790840
206NM_000135.2(FANCA): c.4015delC (p.Leu1339Serfs)deletionLikely pathogenicrs762902309GRCh37Chr 16, 89805693: 89805693
207FANCINM_001113378.1(FANCI): c.2422A> T (p.Lys808Ter)single nucleotide variantLikely pathogenicrs375656231GRCh38Chr 15, 89293963: 89293963
208FANCMNM_020937.3(FANCM): c.1491dupA (p.Gln498Thrfs)duplicationLikely pathogenicrs797045116GRCh38Chr 14, 45159190: 45159190
209MLH3NM_001040108.1(MLH3): c.2116delA (p.Thr706Glnfs)deletionLikely pathogenicrs797045117GRCh38Chr 14, 75047540: 75047540
210WRNNM_000553.4(WRN): c.487_488delGA (p.Asp163Cysfs)deletionLikely pathogenicrs797045118GRCh37Chr 8, 30922562: 30922563
211CHEK2NM_007194.3(CHEK2): c.320-?_592+?dupduplicationLikely pathogenic
212CHEK2NM_007194.3(CHEK2): c.593-1G> Tsingle nucleotide variantLikely pathogenicrs786203229GRCh38Chr 22, 28719486: 28719486
213PALB2NM_024675.3(PALB2): c.2515-1G> Csingle nucleotide variantLikely pathogenicrs587776417GRCh37Chr 16, 23640597: 23640597
214PALB2NM_024675.3(PALB2): c.2587-?_2748+?deldeletionLikely pathogenic
215PALB2NM_024675.3(PALB2): c.3114-?_3201+?dupduplicationLikely pathogenic
216CHEK2NM_007194.3(CHEK2): c.(?_-1)_(*1_?)deldeletionPathogenic
217CHEK2NM_007194.3(CHEK2): c.909-?_1095+?deldeletionPathogenic
218PALB2NM_024675.3(PALB2): c.2470dupT (p.Cys824Leufs)duplicationPathogenicGRCh37Chr 16, 23641005: 23641005
219PALB2NM_024675.3(PALB2): c.3114-?_3201+?deldeletionPathogenic
220BRIP1NM_032043.2(BRIP1): c.1236delA (p.Val413Phefs)deletionPathogenicGRCh37Chr 17, 59876565: 59876565
221BRIP1NM_032043.2(BRIP1): c.1343G> A (p.Trp448Ter)single nucleotide variantPathogenicrs775171520GRCh37Chr 17, 59871088: 59871088
222BRIP1NM_032043.2(BRIP1): c.1383T> G (p.Tyr461Ter)single nucleotide variantPathogenicrs587780875GRCh37Chr 17, 59871048: 59871048
223ATMATM, IVS61DS, 2-BP INS, +2TAinsertionPathogenic
224BRCA1NM_007294.3(BRCA1): c.1016delA (p.Lys339Argfs)deletionPathogenicrs80357618GRCh37Chr 17, 41246532: 41246532
225BRCA1NM_007294.3(BRCA1): c.1018delG (p.Val340Terfs)deletionPathogenicrs80357774GRCh37Chr 17, 41246530: 41246530
226BRCA1NM_007294.3(BRCA1): c.1121delC (p.Thr374Asnfs)deletionPathogenicrs80357612GRCh3